SERGIO DE OLIVA NASCIF

EFEITOS DA GHRELINA, GHRP-6 E GHRH SOBRE A SECREÇÃO DE GH, ACTH E CORTISOL NO HIPERTIREOIDISMO

Tese apresentada à Universidade Federal de São Paulo – Escola Paulista de Medicina para a obtenção do título de Doutor em Ciências

São Paulo

2008

Livros Grátis

SERGIO DE OLIVA NASCIF

EFEITOS DA GHRELINA, GHRP-6 E GHRH SOBRE A SECREÇÃO DE GH, ACTH E CORTISOL NO HIPERTIREOIDISMO

Tese apresentada à Universidade Federal de São Paulo – Escola Paulista de Medicina para a obtenção do título de Doutor em Ciências

Orientadora:

Prof. Dra. Ana Maria Judith Lengyel

Coordenador:

Prof. Dr. Sergio Atala Dib

São Paulo

2008

À minha filha Carolina, ainda tão pequenina, que me tornou uma pessoa mais completa.

À minha amada esposa Karina, companheira de todas as horas, por me incentivar em todas as minhas conquistas.

Aos meus pais Celia e Rogério, pelo apoio permanente e amor incondicional.

À Dra. Ana Maria Lengyel, não só pela brilhante capacidade de orientação e ensinamentos, mas pelo exemplo de dedicação e amor pela ciência, toda a minha admiração.

AGRADECIMENTOS

AGRADECIMENTOS

Aos pacientes e voluntários que participaram dos testes, sem os quais esse estudo não existiria.

Aos Professores da Disciplina de Endocrinologia da UNIFESP pelos ensinamentos durante o curso de Pós-Graduação, em particular ao grupo de Tireóide pelo encaminhamento de pacientes. Ao Prof. Julio Abucham pela convivência agradável e brilhantismo durante a realização dos estudos na Neuroendocrinologia.

Aos Professores da Disciplina de Endocrinologia da Faculdade de Medicina de Sorocaba, Maria Helena Senger, Magali Zampieri, Maria Teresa Quilici e Alexandre Vieira, que proporcionaram um apoio marcante na aquisição de conhecimentos durante os anos de Residência Médica. Um agradecimento especial ao João Carlos Ramos Dias pela amizade fraternal e orientação precisa desde o início da especialização.

Aos colegas de Pós-Graduação da UNIFESP, principalmente do grupo da Neuroendocrinologia, Teresa, Juliana, Elisa, Mariana, Manoel, Erika, Rogério, Priscilla, Marcos e Larissa, pelo agradável convívio. Uma menção especial à Silvia, por todos estes anos de amizade e companheirismo desde o início da Pós-Graduação, e à Patrícia que desempenhou papel fundamental para a conclusão deste estudo.

À Amaryllis Salzano pela atenção que sempre me dispensou. À Filomena, Walkíria e Teresa Kasamatsu pela assistência técnica.

Aos funcionários da Disciplina de Endocrinologia, em especial à Yeda, Ivonete, João, Fátima, Lourdes e Margareth, pela atenção e ajuda.

ÍNDICE

INTRODUÇÃO

INTRODUÇÃO

O controle da secreção pulsátil do hormônio de crescimento (GH) pelos somatotrofos da adenohipófise é resultante de uma complexa interação entre dois peptídeos hipotalâmicos: o hormônio liberador de GH (GHRH), que estimula a secreção de GH, e a somatostatina, que tem um efeito inibitório sobre a liberação deste hormônio (Dieguez *et al.*, 1988). Além do GHRH e da somatostatina, diversos outros fatores modulam a secreção de GH, atuando diretamente sobre a hipófise ou sobre a liberação destes dois peptídeos hipotalâmicos (Lengyel, 1992).

Na década de 70, antes da descoberta do GHRH, Bowers e col. identificaram pequenos peptídeos sintéticos a partir da molécula de met-encefalina que eram capazes de liberar GH. Estudos posteriores baseados em cálculos de energia conformacional, modificações químicas e testes de atividade biológica resultaram no desenvolvimento de peptídeos mais potentes, incluindo um hexapeptídeo denominado *growth hormone-releasing peptide-6* (GHRP-6) (Bowers *et al.*, 1984). Este peptídeo promove a liberação de GH, tanto *in vitro* como *in vivo*, em todas as espécies de animais testadas e este efeito é obtido por diferentes vias de administração, incluindo endovenosa e mesmo por via oral (Ghigo *et al.*, 1997; Isidro & Cordido, 2006). Estudos realizados com estes secretagogos de GH (GHS) nas últimas décadas reforçaram a hipótese de existir um papel fisiológico de tais compostos na regulação da secreção de GH (Dieguez & Casanueva, 2000), uma vez que exercem sua atividade por mecanismo diferente daquele utilizado pelo GHRH (Korbonits & Grossman, 1995). A presença de receptores específicos para os GHS, tanto no hipotálamo quanto na hipófise, sugeria a possível existência de

um peptídeo endógeno semelhante ainda não identificado (Codd *et al.*, 1989; Blake & Smith, 1991; Goth *et al.*, 1992). A clonagem do receptor "órfão" dos GHS, em 1996, comprovou a hipótese da existência de um terceiro sistema de controle da secreção de GH (Howard *et al.*, 1996). Finalmente, em 1999, Kojima e col. clonaram o ligante endógeno dos GHS, que foi isolado a partir de extrato de estômago, e denominado ghrelina. A estrutura deste peptídeo, que é acilado, é completamente diferente dos peptídeos conhecidos e também da estrutura química dos GHS (Kojima *et al.*, 1999). A modificação n-octanoil do resíduo serina na posição 3 da molécula é fundamental para a atividade biológica do peptídeo (Kojima *et al.*, 1999; Bednarek *et al.*, 2000). A ghrelina está presente em altas concentrações no trato gastrointestinal (Kojima *et al.*, 1999; Date *et al.*, 2000a) e, em menores concentrações, no sistema nervoso central, principalmente no núcleo arqueado (Kojima *et al.*, 1999; Shuto *et al.*, 2001).

A ghrelina promove a liberação de GH tanto *in vivo* como *in vitro*, em animais e no homem, de modo dose-dependente (Kojima *et al.*, 1999; Takaya *et al.*, 2000; Date *et al.*, 2000b; Peino *et al.*, 2000). Este peptídeo é o mais potente estímulo para a secreção de GH em humanos, promovendo uma maior liberação de GH quando comparado à hexarelina (um GHS) e ao GHRH em doses equimolares (Arvat *et al.*, 2001). Da mesma forma que os GHS, a ghrelina estimula a secreção de GH através de mecanismos hipofisários e hipotalâmicos (Korbonits *et al.*, 2004). A ghrelina e os GHS ativam os receptores de GHS (GHS-R) em culturas de células hipofisárias *in vitro* (Kojima *et al.*, 1999), porém sua atividade *in vivo* é maior (Arvat *et al.*, 2001), sugerindo que seu principal sítio de ação seja hipotalâmico. Além disso, os efeitos destes

peptídeos são reduzidos ou abolidos na desconexão hipotálamo-hipofisária (Popovic *et al.*, 1995; Popovic *et al.*, 2003). Foi demonstrado que a integridade da via do GHRH é fundamental para a ação da ghrelina e dos GHS (Dickson *et al.*, 1995; Pandya *et al.*, 1998; Maheshwari *et al.*, 1999; Tannenbaum & Bowers, 2001; Tannenbaum *et al.*, 2003). Além disso, a ghrelina e os GHS podem ativar os GHS-R expressos em ¼ dos neurônios produtores de GHRH no núcleo arqueado (Tannenbaum & Bowers, 2001). Foi proposto um modelo de ação da ghrelina que envolve, além da liberação hipotalâmica de GHRH, a amplificação do efeito do GHRH no somatotrofo, e também o antagonismo funcional da somatostatina (Tannenbaum *et al.*, 2003). A ação da ghrelina e dos GHS no somatotrofo ocorre através da ativação do sistema da proteína quinase C, com elevação de diacilglicerol e inositol trifosfato, acarretando aumento do cálcio intracelular (Howard *et al.*, 1996; Chen *et al.*, 1996), ao passo que o GHRH estimula o sistema da proteína quinase A após ativação do AMPc intracelular. (Goth *et al.*, 1992). Mais recentemente, foi demonstrado em somatotrofos de suínos (Malagón *et al.*, 2003) e de babuínos (Kineman & Luque, 2007), que a ghrelina também é capaz de ativar o AMPc e estimular os sistemas de influxo de cálcio intracelular, ação esta mais ampla que a dos GHS sintéticos, o que poderia explicar sua maior potência. A descoberta da ghrelina comprovou a existência de uma terceira via de regulação de secreção de GH. Entretanto, o papel desta via na fisiologia e fisiopatologia da secreção de GH ainda não é conhecido (Lengyel, 2006).

Os hormônios tireoidianos participam da síntese e secreção de GH. Apesar do local preciso e mecanismo de ação ainda serem desconhecidos, há evidências que estes hormônios atuam tanto no hipotálamo quanto na hipófise

(Dieguez *et al.*, 1985; Jones *et al.*, 1990; Valcavi *et al.*, 1992; Giustina & Wehrenberg, 1995).

Distúrbios da função tireoidiana cursam com alterações na secreção de GH (Valcavi *et al.*, 1992). No hipertireoidismo, a responsividade do GH à diversos estímulos farmacológicos, incluindo o GHRH, está diminuída (Burgess *et al.*, 1966; Giustina *et al.*, 1991; Valcavi *et al.*, 1993; Ramos-Dias *et al.*, 1995). Os mecanismos responsáveis por estas alterações não estão claros. Um aumento no tônus hipotalâmico de somatostatina é improvável pois foi demonstrado que compostos que inibem a liberação de somatostatina são incapazes de normalizar a resposta do GH aos estímulos farmacológicos (Yeung, 1973; Valcavi *et al.*, 1991; Ramos-Dias *et al.*, 1995). Embora controverso (Iranmanesh *et al.*, 1991), a diminuição da secreção de GHRH hipotalâmico poderia estar envolvida (Jones *et al.*, 1990; Kamegai *et al.*, 2004), ou poderia haver um efeito direto do excesso de hormônios tireoidianos sobre os somatotrofos (Dieguez *et al.*, 1985; Jones *et al.*, 1990; Valcavi *et al.*, 1992; Giustina & Wehrenberg, 1995).

A ghrelina e os GHS também são capazes de estimular o eixo hipotálamo-hipófise-adrenal em indivíduos normais, sendo que a ghrelina tem um efeito mais potente (Takaya *et al.*, 2000; Arvat *et al.*, 2001). A ação destes peptídeos sobre a liberação de ACTH e cortisol é exclusivamente hipotalâmica, já que não promovem a secreção de ACTH em fragmentos de hipófise *in vitro* (Elias *et al.*, 1995; Kojima *et al.*, 1999), e os GHS-R não foram encontrados em corticotrofos normais (Smith *et al.*, 1997). Além disso, na desconexão hipotálamo-hipofisária o efeito da ghrelina e dos GHS sobre o ACTH e cortisol é abolido (Popovic *et al.*, 1995; Popovic *et al.*, 2003). Foi demonstrado que o

GHRP-6 estimula a liberação de arginina-vasopressina (AVP) em fragmentos hipotalâmicos *in vitro* (Korbonits *et al.*, 1999b), ao passo que a ghrelina tem uma ação mais ampla, promovendo a liberação de AVP, CRH e NPY (Wren *et al.*, 2002), com um efeito predominante na secreção de AVP (Mozid *et al.*, 2003). Embora controverso, os GHS e a ghrelina estimulam a secreção de ACTH em humanos provavelmente através do aumento da liberação hipotalâmica de AVP (Korbonits *et al.*, 1999a; Coiro *et al.*, 2005).

Estudos prévios sugerem que os hormônios tireoidianos podem participar da regulação do eixo hipotálamo-hipófise adrenal por mecanismos que ainda não estão completamente elucidados. Classicamente, sabe-se que na tireotoxicose há aumento compensatório da taxa de produção de cortisol secundário a uma maior degradação (Levin & Daughaday, 1955; Peterson, 1958; Gordon & Southren, 1977). Dessa forma, no hipertireoidismo prolongado, as adrenais estão estimuladas cronicamente e, dependendo da severidade clínica e da duração da doença, a resposta de cortisol após diferentes estímulos como ACTH, CRH e teste de tolerância à insulina pode estar diminuída (Jackson *et al.*, 1966; Goswami & Kochupillai, 2001; Tsatsoulis *et al.*, 2000; Yamakita *et al.*, 2001). Entretanto, resposta normal de cortisol após indução de hipoglicemia também tem sido observada (Jackson *et al.*, 1966; Giustina *et al.*, 1971; Brauman *et al.*, 1973; Moghetti *et al.*, 1994). O comprometimento da reserva adrenocortical durante o hipertireoidismo, e sua normalização após obtenção do eutireoidismo, pode estar relacionada à diminuição dos níveis da globulina ligadora de corticoesteróides (CBG) nos indivíduos não-tratados, uma vez que o tratamento do hipertireoidismo cursa com aumento nos níveis de CBG (Dumoulin *et al.*, 1995; Mishra *et al.*, 2007).

Entretanto, a elevação da concentração de corticosterona no líquor de ratos tireotóxicos e também da razão cortisol/CBG no hipertireoidismo (Kamilaris *et al.*, 1991; Johnson *et al.*, 2005; Mishra *et al.*, 2007) sugere que um aumento de cortisol circulante está realmente presente por excesso de secreção de cortisol na vigência de elevação dos hormônios tireoidianos. Essa hipótese é reforçada pelos poucos estudos que mostram aumento dos níveis de ACTH basal (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Mishra *et al.*, 2007) e após estímulo com CRH e hipoglicemia em indivíduos portadores de hipertireoidismo (Moghetti *et al.*, 1994; Lizcano & Salvador, 2008).

A administração de ghrelina também acarreta aumento dos níveis de glicose plasmática em indivíduos normais (Broglio *et al.*, 2001), provavelmente por estimular a liberação de glicose hepática (Gauna *et al.*, 2005). Esta ação é independente do GH, uma vez que está presente mesmo em pacientes com deficiência de GH (Gauna *et al.*, 2004). Sabe-se que o hipertireoidismo pode cursar com resistência à insulina e hiperinsulinemia (O'Meara *et al.*, 1993; Dimitriadis *et al.*, 2008) mas não há relatos sobre os efeitos da ghrelina/GHS nos níveis circulantes de glicose em pacientes com excesso de hormônios tireoidianos.

OBJETIVOS

OBJETIVOS

(1) Avaliar os efeitos da ghrelina e do GHRP-6 sobre a liberação GH e glicose em pacientes com hipertireoidismo. Os níveis de GH após a administração de GHRH também foram estudados.

(2) Avaliar os efeitos da ghrelina e do GHRP-6 sobre a liberação de ACTH e cortisol em pacientes tireotóxicos.

REFERÊNCIAS BIBLIOGRÁFICAS

REFERÊNCIAS BIBLIOGRÁFICAS

Arvat E, Maccario M, di Vito L, *et al.* 2001 Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 86:1169-1174.

Bednarek MA, Feighner SD, Pong SS, *et al.* 2000 Structure-function studies on the new growth hormone-releasing peptide ghrelin: minimal sequence necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 43:4370-4376.

Blake AD & Smith RG. 1991 Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH$_2$ stimulate growth hormone release through distinct receptor sites. J Endocrinol 129:11-19.

Bowers CY, Momany FA, Reynolds GA, *et al.* 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545.

Brauman H, Smets P, Corvilain J. 1973 Comparative study of growth response to hypoglycemia in normal subjects and in patients with primary myxedema or hyperthyroidism before and after treatment. J Clin Endocrinol Metab 36:1162-1174.

Broglio F, Arvat E, Benso A, *et al.* 2001 Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86:5083-5086.

Burgess JA, Smith BR, Merimee TJ. 1966 Growth hormone in thyrotoxicosis: effect of insulin-induced hypoglycemia. J Clin Endocr 26:1257-1260.

Chen C, Wu D, Clarke IJ. 1996 Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J Endocrinol 148:381-386.

Codd EE, Shu AY, Walker RF. 1989 Binding of growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 28:1139-1144.

Coiro V, Saccani-Jotti G, Minelli R, *et al.* 2005 Adrenocorticotropin/cortisol and arginine-vasopressin secretory patterns in response to ghrelin in normal men. Neuroendocrinology 81:103-106.

Date Y, Kojima M, Hosoda H, *et al.* 2000a Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255-4261.

Date Y, Murakami N, Kojima M, *et al.* 2000b Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun 275:477-480.

Dickson SL, Doutrelant-Viltart O, Leng G. 1995 GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. J Endocrinol 146:519-526.

Dieguez C & Casanueva FF. 2000 Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. Eur J Endocrinol 142:413-417.

Dieguez C, Foord SM, Peters JR, Hall R, Scanlon MF. 1985 The effects of thyroid hormone deprivation in vivo and in vitro on growth hormone (GH) responses to human pancreatic (tumour) GH-releasing factor (1-40) by dispersed rat anterior pituitary cells. Endocrinology 116:1066-1070.

Dieguez C, Page MD, Scanlon MF. 1988 Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol 28:109-143.

Dimitriadis G, Mitrou P, Lambadiari V, *et al.* 2008 Insulin-stimulated rates of glucose uptake in muscle in hyperthyroidism: the importance of blood flow. J Clin Endocrinol Metab 93:2413-2415.

Dumoulin SC, Perret BP, Bennet AP, Caron PJ. 1995 Opposite effects of thyroid hormones on binding proteins for steroid hormones (sex hormone-binding globulin and corticosteroid-binding globulin) in humans. Eur J Endocrinol 132:594-598.

Elias KA, Ingle GS, Burnier JP, *et al.* 1995 In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 136:5694-5699.

Gauna C, Delhanty PJ, Hofland LJ, *et al.* 2005 Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 90:1055-1060.

Gauna C, Meyler FM, Janssen JA, *et al.* 2004 Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035-5042.

Ghigo E, Arvat E, Muccioli G, Camanni F. 1997 Growth hormone-releasing peptides. Eur J Endocrinol 136:445-460.

Giustina A, Buffoli MG, Bussi AR, Wehrenberg WB. 1991 Acute effects of clonidine and growth-hormone-releasing hormone on growth hormone secretion in patients with hyperthyroidism. Horm Res 36:192-195.

Giustina A & Wehrenberg WB. 1995 Influence of thyroid hormones on the regulation of growth hormone secretion. Eur J Endocrinol 133:646-653.

Giustina G, Reschini E, Valentini F, Cantalamessa L. 1971 Growth hormone and cortisol responses to insulin-induced hypoglycemia in thyrotoxicosis. J Clin Endocr 32:571-574.

Gordon GG & Southren AL. 1977 Thyroid-hormone effects on steroid-hormone metabolism. Bull N Y Acad Med 53:241-254.

Goswami R & Kochupillai N. 2001 Adrenocortical reserves in patients with Graves' disease. Eur J Endocrinol 144:85.

Goth MI, Lyons CE, Canny BJ, *et al.* 1992 Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130:939-944.

Howard AD, Feighner SD, Cully DF, *et al.* 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977.

Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. 1991 Nature of altered growth hormone secretion in hyperthyroidism. J Clin Endocrinol Metab 72:108-115.

Isidro ML & Cordido F. 2006 Growth hormone secretagogues. Comb Chem High Throughput Screen 9:175-180.

Jackson IMD, Hassan THA, Prentice CRM, Browning MCK. 1966 Insulin-induced hypoglycemia as a test of pituitary-adrenal function in thyrotoxicosis. J Clin Endocr 26:545-549.

Johnson EO, Kamilaris TC, Calogero AE, Gold PW, Chrousos GP. 2005 Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic-pituitary-adrenal axis. Eur J Endocrinol 153:177-185.

Jones PM, Burrin JM, Ghatei MA, O´halloran DJ, Legon S, Bloom SR. 1990 The influence of thyroid hormone status on the hypothalamo-hypophyseal growth hormone axis. Endocrinology 126:1374-1379.

Kamegai J, Tamura H, Shimizu T, *et al.* 2004 The role of pituitary ghrelin in growth hormone (GH) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. Endocrinology 145:3731-3738.

Kamilaris TC, DeBold CR, Johnson EO, *et al.* 1991 Effects of short and long duration hypothyroidism and hyperthyroidism on the plasma adrenocorticotropin and corticosterone responses to ovine corticotropin-releasing hormone in rats. Endocrinology 128:2567-2576.

Kineman RD & Luque RM. 2007 Evidence that ghrelin is as potent as growth hormone (GH)-releasing hormone (GHRH) in releasing GH from primary pituitary cell cultures of a nonhuman primate (Papio anubis), acting through intracellular signaling pathways distinct from GHRH. Endocrinology 148:4440-4449.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660.

Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. 2004 Ghrelin – a hormone with multiple functions. Front Neuroendocrinol 25:27-68.

Korbonits M & Grossman AB. 1995 Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 6:43-49.

Korbonits M, Kaltsas G, Perry LA, *et al.* 1999a The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 84:2489-2495.

Korbonits M, Little JA, Forsling ML, *et al.* 1999b The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 11:521-528.

Lengyel AMJ. 1992 *GH secretion in obesity.* In Regulation of growth hormone and somatic growth (ed, De La Cruz LF), pp 227-251. Elsevier Science Publishers, Holland.

Lengyel AM. 2006 Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res. 39:1003-1011.

Levin ME & Daughaday WH. 1955 The influence of the thyroid on adrenocortical function. J Clin Endocrinol Metab 15:1494-1510.

Lizcano F & Salvador J. 2008 Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol (Epub ahead of print).

Maheshwari HG, Rahim A, Shalet SM, Baumann G. 1999 Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. J Clin Endocrinol Metab 84:956-959.

Malagón MM, Luque RM, Ruiz-Guerrero E, *et al.* 2003 Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology 144:5372-5380.

Mishra SK, Gupta N, Goswami R. 2007 Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 μg ACTH stimulation in patients with

hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 92:1693-1696.

Moghetti P, Castello R, Tosi F, *et al.* 1994 Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects. J Clin Endocrinol Metab 78:169-173.

Mozid AM, Tringali G, Forsling ML, *et al.* 2003 Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res 35:455-459.

O'Meara NM, Blackman JD, Sturis J, Polonsky KS. 1993 Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab 76:79-84.

Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. 1998 Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab 83:1186-1189.

Peino R, Baldelli R, Rodriguez-Garcia J, *et al.* 2000 Ghrelin-induced growth hormone secretion in humans Eur J Endocrinol 143:11-14.

Peterson RE. 1958 The influence of the thyroid on adrenal cortical function. J Clin Invest 37:736-743.

Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. 1995 Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 80:942-947.

Popovic V, Miljic D, Micic D, *et al.* 2003 Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 88:3450-3453.

Ramos-Dias JC, Yateman M, Camacho-Hübner C, Grossman A, Lengyel AMJ. 1995 Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. Clin Endocrinol 43:583-589.

Shuto Y, Shibasaki T, Wada K, *et al.* 2001 Generation of polyclonal antiserum against the growth hormone secretagogue receptor (GHS-R): evidence that the GHS-R exists in the hypothalamus, pituitary and stomach of rats. Life Sci 68:991-996.

Smith RG, Van der Ploeg LH, Howard AD, *et al.* 1997 Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621-645.

Takaya K, Ariasu H, Kanamoto N, *et al.* 2000 Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocrinol Metab 85:4908-4911.

Tannenbaum GS & Bowers CY. 2001 Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine 14:21-27.

Tannenbaum GS, Epelbaum J, Bowers CY 2003 Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144:967-974.

Tsatsoulis A, Johnson EO, Kalogera CH, Seferiadis K, Tsolas O. 2000 The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 142:231-235.

Valcavi R, Dieguez C, Zini M, *et al.* 1991 Effect of pyridostigmine and pirenzepine on GH responses to GHRH in hyperthyroid patients. Clin Endocrinol 35:141-144.

Valcavi R, Dieguez C, Zini M, Muruais C, Casanueva F, Portioli I. 1993 Influence of hyperthyroidism on growth hormone secretion. Clin Endocrinol 38:515-522.

Valcavi R, Zini M, Portioli I. 1992 Thyroid hormones and growth hormone secretion. J Endocrinol Invest 15:313-330.

Wren AM, Small CJ, Fribbens CV, *et al.* 2002 The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. Neuroendocrinology 76:316-324.

Yamakita N, Murai T, Kokubo Y, Hayashi M, Akai A, Yasuda K. 2001 Dehydroepiandrosterone sulphate is increased and dehydroepiandrosterone-response to corticotrophin-releasing hormone is decreased in the hyperthyroid state compared with the euthyroid state. Clin Endocrinol 55:797-803.

Yeung RTT. 1973 Effect of propranolol on plasma growth hormone response in insulin-induced hypoglycemia in thyrotoxic patients. J Clin Endocrinol Metab 37:968-971.

DECREASED GHRELIN-INDUCED GH RELEASE IN THYROTOXICOSIS: COMPARISON WITH GH-RELEASING PEPTIDE-6 (GHRP-6) AND GHRH

Estudo 1

Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH

Sergio Oliva Nascif · Silvia Regina Correa-Silva ·
Marcos Roberto Silva · Ana-Maria Judith Lengyel

Abstract In thyrotoxicosis GH response to several stimuli is impaired, but there is no data on ghrelin-induced GH release in these patients. Ghrelin is a potent GH secretagogue and it also increases glucose levels in men. The aim of this study was to evaluate the effects of ghrelin (1 µg/kg), GHRP-6 (1 µg/kg) and GHRH (100 µg), i.v., on GH levels in 10 hyperthyroid patients and in 8 controls. Glucose levels were also measured during ghrelin and GHRP-6 administration. In control subjects and hyperthyroid patients peak GH (µg/l; mean ± SE) values after ghrelin injection (controls: 66.7 ± 13.6; hyper: 19.3 ± 2.4) were significantly higher than those obtained after GHRP-6 (controls: 26.7 ± 5.1; hyper: 12.6 ± 1.3) and GHRH (controls: 13.5 ± 4.3; hyper: 5.3 ± 1.3). There was a significant decrease in GH responsiveness to ghrelin, GHRP-6 and GHRH in the hyperthyroid group compared to controls. In control subjects and hyperthyroid patients basal glucose (mmol/l) values were 4.5 ± 0.1 and 4.7 ± 0.2, respectively. There was a significant increase in glucose levels 30 min after ghrelin injection (controls: 4.9 ± 0.1; hyper: 5.2 ± 0.2), which remained elevated up to 120 min. When the two groups were compared no differences in glucose values were observed. GHRP-6 administration was not able to increase glucose levels in both groups. Our data shows that GH release after ghrelin, GHRP-6 and GHRH administration is decreased in thyrotoxicosis. This suggests that thyroid hormone excess interferes with GH-releasing pathways activated by these peptides. Our results also suggest that ghrelin's ability to increase glucose levels is not altered in thyrotoxicosis.

Keywords Ghrelin · Thyrotoxicosis · GH · GHRP-6 · GHRH

Introduction

Pulsatile GH secretion is modulated by an interplay between hypothalamic GHRH and somatostatin. Several studies have proposed that GH secretagogues (GHS) might also have a role in this process, acting at both pituitary and hypothalamic receptors [1–3]. Ghrelin, the endogenous ligand of GHS-receptor (GHS-R), has been recently discovered in the stomach, but is also present in the hypothalamic arcuate nucleus [4–6]. Interestingly, the chemical structure of this acylated peptide is different from GHS [4]. The post-translational fatty acid chain modification (n-octanoyl residue) is essential for its biological effects on GH release and also on the increase in circulating glucose levels [4, 6]. Non-acylated ghrelin, which is the main circulating form, might have non-endocrine actions [4]. Ghrelin can cross the blood–brain barrier [7] and is able to release GH in a potent manner after i.v. injection both in animals and in men [8–10]. The main site of action of this peptide is at hypothalamic level as its GH-releasing property is greatly decreased in hypothalamic–pituitary disconnection, similarly to what is observed with GHS [11, 12]. However, ghrelin and GHS also act at pituitary level, through different receptors and intracellular mechanisms than those of

S. O. Nascif (✉) · S. R. Correa-Silva ·
M. R. Silva · A.-M. J. Lengyel
Division of Endocrinology, Universidade Federal de São Paulo, UNIFESP/EPM, Rua Pedro de Toledo, 910, 04039-002 São Paulo, SP, Brazil
e-mail: snascif@uol.com.br

GHRH [4, 13, 14]. It has been proposed that GHS activate hypothalamic GHRH release, amplify GHRH effects at the somatotroph and also act as functional somatostatin antagonists [15, 16]. Ghrelin is also able to increase circulating glucose levels in humans, by a direct hepatic action [17, 18]. It has been recently shown that non-acylated ghrelin counteracts the increase in glucose levels induced by the acylated peptide [19].

Thyroid hormones participate in GH synthesis and secretion. Their site and mechanism of action are still unknown, but theses hormones could act at both pituitary and hypothalamic level [20–23]. Impaired GH release has been found in patients with thyroid dysfunctions [22]. In hyperthyroidism a blunted GH response to several pharmacological stimuli, such as GHRH, has been demonstrated [24–27]. We have previously shown that GH response to GHRP-6 is normal in thyrotoxicosis while GH responsiveness to GHRH is decreased [28]. The mechanisms involved in these alterations are unclear. An increase in hypothalamic somatostatin is unlikely, as compounds that inhibit somatostatin release are unable to normalise the blunted GH response to pharmacological stimuli in thyrotoxicosis [27, 29, 30]. Although controversial [31], a decrease in hypothalamic GHRH secretion could be involved [21, 32] and/or a direct effect of thyroid hormones at the somatotroph [20–23]. The effect of thyroid hormone excess on hypothalamic ghrelin has not been studied, but a decrease in gastric [33] and pituitary ghrelin mRNA levels has been reported in thyrotoxic rats [32]. It has also been shown that circulating ghrelin levels are decreased in hyperthyroidism, both in rats and in men [33–35]. There is no data in the literature about the effects of ghrelin on GH release in hyperthyroidism both in men and in animals. As ghrelin and GHS have different structures and several receptors for these peptides are likely to exist [4, 5, 36], the aim of this work was to evaluate the GH and glucose-releasing effects of ghrelin in thyrotoxicosis, in comparison with GHRP-6. GHRH-induced GH release was also studied, as this peptide releases GH by different pathways than those of GHS.

Subjects and methods

Subjects

We studied 10 patients (eight women and two men) with hyperthyroidism due to Graves' disease. Their mean age was 33 years (range, 26–44), with a mean body mass index (BMI) of 22.8 kg/m^2 (range, 20.3–26.5). All patients had diffuse goiter and/or thyroid ophthalmopathy and had clinical symptoms and signs of thyrotoxicosis. Three subjects had been previously treated with antithyroid drugs alone or associated with beta-adrenoreceptor blockers and one of them had been previously submitted to radioiodine therapy. The diagnosis of hyperthyroidism was confirmed by high levels of free T4 (95.2 ± 15.4 pmol/l; normal range 10.3–21.9), total T3 (9.0 ± 1.2 nmol/l; normal range 0.9–2.8), and by suppressed levels of TSH (0.02 ± 0.01 mU/l; normal range 0.5–5.5). TSH receptor antibody (TRAb) was positive in seven patients, varying from 11 to 300 U/l (normal range <11). None of the patients had other associated diseases and was taking any medication for at least 2 months before the study.

Eight subjects (three women and five men) with no history of thyroid disease were also studied as a control group. Their mean age was 30 years (range, 20–36) and their mean BMI was 23.2 kg/m^2 (19.5–25.7). All subjects had normal thyroid function and were free of any medication at the time of the study. The women were tested in the early follicular phase of their menstrual cycle.

Study protocol

The experimental protocol was approved by the ethics committee of Universidade Federal de São Paulo, and all subjects were studied after giving informed consent. The tests were performed after an overnight fast and the subjects remained recumbent throughout it. Each subject underwent three tests, randomly, with an interval of at least 48 h between them. Forty-five minutes before starting the test, an indwelling catheter was inserted into an antecubital vein and kept patent by slow 0.9% saline infusion. After the first blood sample each subject received acylated ghrelin (Neosystem, Strasbourg, France) at a dose of 1 µg/kg, GHRP-6 (Bachem, San Carlos, USA) at a dose of 1 µg/kg, or GHRH (Clinalfa, Läufelfingen, Switzerland) at a dose of 100 µg, i.v., in bolus. Blood samples were collected every 15 min until 120 min for subsequent GH determination. Glucose levels were measured every 30 min. Baseline blood samples were also obtained for free T4, total T3 and TSH. Control subjects were also submitted to the tests using the same procedure as above.

Assays

Serum GH was measured in duplicate by immunofluorometric assay (Wallac Oy, Turku, Finland). The sensitivity of the method is 0.01 µg/l, with mean

intra- and interassay coefficients of variation of 6.7 and 7%, respectively. Free T4, total T3 and TSH were determined by immunochemiluminometric assays (Advia Centaur, Bayer, USA). TRAb was measured by a radioimmunoassay (RSR Limited, Cardiff, United Kingdom). Plasma glucose levels were determined by the hexokinase method (Advia 1650, Bayer, USA).

Statistical analysis

Friedman's analysis of variance was performed to compare GH and glucose levels after the injection of each peptide and to compare GH responses in the same group. The Mann–Whitney rank sum test was performed for comparisons between thyrotoxic patients and control subjects. The responses were also analysed by the area under the curve (AUC), which was calculated by trapezoidal integration. Undetectable GH levels were considered to be equal to 0.01 µg/l for statistical purposes. Results are shown as mean ± SE. $P < 0.05$ was considered statistically significant.

Results

In controls subjects peak GH (µg/l) and AUC (µg/l 120 min) values after ghrelin administration (66.7 ± 13.6; 3,773 ± 878) were significantly higher than those obtained after GHRP-6 (26.7 ± 5.1; 1,454 ± 333) and GHRH (13.5 ± 4.3; 1,038 ± 346) (Figs. 1 and 2). No significant differences were seen in GH responses to GHRP-6 and GHRH, despite the higher magnitude of GH levels after GHRP-6.

In thyrotoxicosis peak GH values after ghrelin injection (19.3 ± 2.4) were significantly higher than after GHRP-6 (12.6 ± 1.3) and GHRH (5.3 ± 1.3). In terms of AUC values, ghrelin (873 ± 98) and GHRP-6-induced (652 ± 78) GH release did not reach statistical significance, while both were higher than that of GHRH (467 ± 84).

When thyrotoxic patients were compared to controls, there was a significant decrease in GH responsiveness to ghrelin, GHRP-6 and GHRH in the hyperthyroid group, both in terms of peak GH and AUC values, except for GHRH AUC, which did not reach statistical significance despite lower levels, due to the variability of responses.

In control subjects and hyperthyroid patients basal glucose (mmol/l) values were 4.5 ± 0.1 and 4.7 ± 0.2, respectively (Fig. 3). There was a significant increase in glucose levels 30 min after ghrelin injection (controls: 4.9 ± 0.1; hyper: 5.2 ± 0.2), which remained elevated up to 120 min. The absolute increment was 0.4 mmol/l in controls and 0.5 mmol/l in thyrotoxic patients, while the AUC (mmol/l 120 min) was 10,298 ± 223 and 10,727 ± 322, respectively. When the two groups were compared, no differences in glucose values before or after ghrelin administration were observed. GHRP-6 administration was not able to increase glucose levels in both groups.

No significant differences in age and BMI were observed in the two study groups.

Side effects

Hunger sensation was reported in five thyrotoxic patients and in five controls after ghrelin administration. Nausea was seen after GHRP-6 in four patients and in one control. Most subjects experienced transient facial flushing after GHRH injection.

Fig. 1 Mean GH values after ghrelin (1 µg/kg), GHRP-6 (1 µg/kg) and GHRH (100 µg) administration in 8 control subjects and in 10 hyperthyroid patients (mean ± SE)

Fig. 2 Mean peak GH levels after ghrelin (1 μg/kg), GHRP-6 (1 μg/kg) and GHRH (100 μg) administration in 8 control subjects and in 10 hyperthyroid patients (mean ± SE; *$P < 0.05$ compared to GHRP-6 and GHRH in each group; NS, not significant)

Fig. 3 Mean glucose values after ghrelin (1 μg/kg) administration in 8 control subjects and in 10 hyperthyroid patients (mean ± SE)

Discussion

In our study GH responsiveness to ghrelin in normal subjects was higher than seen with GHRP-6 and GHRH, confirming a previous report with another GHS, hexarelin [10].

In patients with hyperthyroidism peak GH values after ghrelin were also higher than with GHRP-6 and GHRH, which could be due to the greater potency of ghrelin in relation to the other peptides [10]. It is also possible that thyroid hormone excess has less impact on ghrelin-modulated pathways of GH release.

When the two groups were compared, a significant decrease in GH response to ghrelin was observed in

thyrotoxic patients. Moreover, in hyperthyroidism peak GH values after GHRH were also blunted, confirming earlier studies [25–27]. However, surprisingly, we also found a decrease in GH response to GHRP-6, which is in contrast to our previous report showing normal GH response to GHRP-6 associated with blunted GH responsiveness to GHRH in thyrotoxicosis [28]. The reasons for these divergent findings are not clear. When we compared these two studies, despite a trend to higher T3 and free T4 levels in our actual work, no significant differences in the degree of thyrotoxicosis were observed. However, in the present report hyperthyroid patients were somewhat older and with slightly higher BMI, which eventually could have contributed to the observed decrease in GH responsiveness to GHRP-6 [37, 38]. It has been previously suggested that alterations in hypothalamic–pituitary adrenal function in thyrotoxicosis become more pronounced as the duration of thyroid dysfunction increases [39]. Whether the GH axis is also progressively inhibited during long-term exposure to thyroid hormone excess is still unknown. In our data there were no apparent differences in the duration of thyrotoxicosis in the two studies (data not shown). Another possibility would be related to the different GH assays employed in these reports. In the present work GH was determined by a specific 22 kDa isoform assay, while in our former study an assay which measures both 22 kDa and 20 kDa isoforms was used. Although no changes in GH molecular forms have been reported in baseline blood samples from hyperthyroid patients [40] it is not known whether the proportion of each isoform is maintained after simulation with GHRP-6. Interestingly, Marino et al. [41] have previously shown that the use of assays which are non-specific for the 22 kDa isoform could overestimate serum GH levels in some circumstances.

Our data show that thyroid hormone excess interferes with ghrelin-activated pathways of GH release, which is a novel finding. However, the mechanisms involved in the decreased GH response to ghrelin in thyrotoxicosis are still unknown. A decrease in circulating ghrelin levels has been described in hyperthyroid patients and could eventually be implicated [34, 35]. However, patients with gastrectomy, with low ghrelin levels, have an enhanced sensitivity to ghrelin-induced GH release [42]. Ghrelin and GHS modulate GH secretion acting at both hypothalamic and pituitary level [2, 4, 11, 12]. In patients with hypothalamic–pituitary disconnection there is a major decrease of GH release after the administration of these compounds, indicating that their main site of action is the hypothalamus [11, 12]. GHS and ghrelin activate

GHS-R, which are present in GHRH neurons in the arcuate nucleus [16]. Moreover, for their full effect to occur an intact GHRH system is necessary [16, 43]. Thyroid hormones could interfere with hypothalamic mechanisms and/or with the different receptors and intracellular pathways activated by GHRH and GHS/ghrelin at the somatotroph. GHRH and GHS/ghrelin bind to specific pituitary receptors, but there is evidence of cross-talk between them [44]. GHRH stimulates cyclic AMP and protein-kinase A pathways [13], while ghrelin/GHS activate protein-kinase C transduction systems, via inositol triphosphate [2, 14]. In porcine somatotrophs ghrelin stimulates several interdependent pathways of GH release [45]. Interestingly, it has been demonstrated that glucocorticoids downregulate human GHS-R [46], which could eventually interfere with both ghrelin/GHS stimulated pathways at the somatotroph and also with GHS-R located in hypothalamic GHRH neurons [16]. This could be a hypothetical mechanism to explain the decreased GH response to GHS and ghrelin in patients with Cushing's disease [47, 48]. However, differently than glucocorticoids, thyroid hormones either increase [46] or do not alter human GHS-R [49]. Therefore, it is unlikely that this mechanism is involved in the blunted GH responsiveness to ghrelin/GHS in thyrotoxicosis. We have previously shown that a decrease of circulating T3 levels, with iopanoic acid administration for 15 days, is able to increase, although not normalise, GH responsiveness to GHRH in patients with thyrotoxicosis, indicating that T3 might interfere with GH-releasing pathways [50]. Furthermore, it has been previously suggested that there is an impairment of hypothalamic GHRH production in thyroid hormone excess [21]. In hyperthyroid rats a decrease in hypothalamic GHRH mRNA levels has been demonstrated [21, 32]. If also true for humans, this could eventually explain our findings as chronic GHRH deficiency decreases GH release after the acute administration of ghrelin/GHS and also of GHRH [11, 12, 51]. However, further studies are necessary to substantiate this hypothesis.

It has been recently demonstrated that the increase in glucose values after acylated ghrelin administration is independent of GH, as it is preserved in GH-deficient patients [52]. Moreover, acylated ghrelin enhances glucose release from porcine hepatocytes in culture, while the unacylated peptide has the opposite effect [18]. In our study ghrelin injection induced a significant rise in circulating glucose values in hyperthyroid patients, which was similar to that observed in control subjects. GHRP-6 administration did not alter glucose levels in both groups, confirming earlier studies [17, 53].

Therefore, our data suggest that thyroid hormone excess does not impair ghrelin's ability to increase glucose levels from hepatocytes.

In summary, in patients with thyrotoxicosis there is a decrease in ghrelin-induced GH release, which is a novel finding. Peak GH levels after ghrelin are higher than those observed with GHRP-6 and GHRH, which could be due to the greater potency of this new peptide. Our results suggest that thyroid hormone excess interferes with hypothalamic and pituitary mechanisms of GH release activated by both ghrelin/GHS and GHRH. Further studies are necessary, however, to elucidate the mechanisms involved in these alterations. Our data also suggest that the ability of ghrelin to increase glucose levels is not impaired in thyrotoxicosis.

References

1. Bowers CY, Momany FA, Reynolds GA, Hong A (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537–1545
2. Howard AD, Feighner SD, Cully DF et al (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974–977
3. Arvat E, di Vito L, Maccagno B et al (1997) Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 18:885–891
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth hormone-releasing hormone acylated peptide from stomach. Nature 402:656–660
5. Gnanapavan S, Kola B, Bustin SA et al (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988–2991
6. van der Lely AJ, Tschop M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426–457
7. Banks WA, Tschop M, Robinson SM, Heiman ML (2002) Extent and direction of ghrelin transport across the blood–brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 302:822–827
8. Takaya K, Ariyasu H, Kanamoto N et al (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908–4911
9. Peino R, Baldelli R, Rodriguez-Garcia J et al (2000) Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol 143:11–14

10. Arvat E, Maccario M, Di Vito L et al (2001) Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 86:1169–1174

11. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF (1995) Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 80:942–947

12. Popovic V, Miljic D, Micic D et al (2003) Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 88:3450–3453

13. Goth MI, Lyons CE, Canny BJ, Thorner MO (1992) Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130:939–944

14. Chen C, Wu D, Clarke IJ (1996) Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J Endocrinol 148:381–386

15. Smith RG, Van der Ploeg LH, Howard AD et al (1997) Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621–645

16. Tannenbaum GS, Bowers CY (2001) Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine 14:21–27

17. Broglio F, Arvat E, Benso A et al (2001) Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86:5083–5086

18. Gauna C, Delhanty PJ, Hofland LJ et al (2005) Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 90:1055–1060

19. Broglio F, Gottero C, Prodam F et al (2004) Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 89:3062–3065

20. Dieguez C, Foord SM, Peters JR, Hall R, Scanlon MF (1985) The effects of thyroid hormone deprivation in vivo and in vitro on growth hormone (GH) responses to human pancreatic (tumor) GH-releasing factor (1-40) by dispersed rat anterior pituitary cells. Endocrinology 116:1066–1070

21. Jones PM, Burrin JM, Ghatei MA, O'Halloran DJ, Legon S, Bloom SR (1990) The influence of thyroid hormone status on the hypothalamo-hypophyseal growth hormone axis. Endocrinology 126:1374–1379

22. Valcavi R, Zini M, Portioli I (1992) Thyroid hormones and growth hormone secretion. J Endocrinol Invest 15:313–330

23. Giustina A, Wehrenberg WB (1995) Influence of thyroid hormones on the regulation of growth hormone secretion. Eur J Endocrinol 133:646–653

24. Burgess JA, Smith BR, Merimee TJ (1966) Growth hormone in thyrotoxicosis: effect of insulin-induced hypoglycemia. J Clin Endocrinol Metab 26:1257–1260

25. Giustina A, Buffoli MG, Bussi AR, Wehrenberg WB (1991) Acute effects of clonidine and growth-hormone-releasing hormone on growth hormone secretion in patients with hyperthyroidism. Horm Res 36:192–195

26. Valcavi R, Dieguez C, Zini M, Muruais C, Casanueva F, Portioli I (1993) Influence of hyperthyroidism on growth hormone secretion. Clin Endocrinol 38:515–522

27. Ramos-Dias JC, Yateman M, Camacho-Hübner C, Grossman A, Lengyel AMJ (1995) Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. Clin Endocrinol 43:583–589

28. Ramos-Dias JC, Pimentel-Filho F, Reis AF, Lengyel AMJ (1996) Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab 81:1343–1346

29. Yeung RTT (1973) Effect of propranolol on plasma growth hormone response in insulin-induced hypoglycemia in thyrotoxic patients. J Clin Endocrinol Metab 37:968–971

30. Valcavi R, Dieguez C, Zini M et al (1991) Effect of pyridostigmine and pirenzepine on GH responses to GHRH in hyperthyroid patients. Clin Endocrinol 35:141–144

31. Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD (1991) Nature of altered growth hormone secretion in hyperthyroidism. J Clin Endocrinol Metab 72:108–115

32. Kamegai J, Tamura H, Shimizu T et al (2004) The role of pituitary ghrelin in growth hormone (GH) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. Endocrinology 145:3731–3738

33. Caminos JE, Seoane LM, Tovar SA, Casanueva FF, Dieguez C (2002) Influence of thyroid status and growth hormone deficiency on ghrelin. Eur J Endocrinol 147:159–163

34. Riis ALD, Hansen TK, Moller N, Weeke J, Jorgensen JOL (2003) Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab 88:853–857

35. Rojdmark S, Calissendorff J, Danielsson O, Brismar K (2005) Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27:55–61

36. Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R (2001) Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 24:7–9

37. Arvat E, Gianotti L, Grottoli S et al (1994) Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 79:1440–1443

38. Cordido F, Penalva A, Dieguez C, Casanueva FF (1993) Massive growth hormone (GH)discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 76:819–823

39. Johnson EO, Kamilaris TC, Calogero AE, Gold PW, Chrousos GP (2005) Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic–pituitary–adrenal axis. Eur J Endocrinol 153:177–185

40. Tsushima T, Katoh Y, Miyachi Y et al (1999) Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH. J Clin Endocrinol Metab 84:317–322

41. Marino R, Chaler E, Warman M et al (2003) The serum growth hormone (GH) response to provocative tests is dependent on type of assay in autosomal dominant isolated GH deficiency because of an ARG^{183}HIS (R183H) GH-I gene mutation. Clin Chem 49:1002–1005

42. Popovic V, Miljic D, Pekic S et al (2005) Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. J Clin Endocrinol Metab 90:2187–2191

43. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA (1998) Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone

for maximal GH stimulation. J Clin Endocrinol Metab 83:1186–1189

44. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB (2004) Ghrelin – a hormone with multiple functions. Front Neuroendocrinol 25:27–68

45. Malagón MM, Luque RM, Ruiz-Guerrero E et al (2003) Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology 144:5372–5380

46. Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM (2001) Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 142:2649–2659

47. Leal-Cerro A, Torres E, Soto A et al (2002) Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses. Neuroendocrinology 76:390–396

48. Giordano R, Picu A, Pagotto U et al (2005) The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. Eur J Endocrinol 153:535–543

49. Kaji H, Kishimoto M, Kirimura T et al (2001) Hormonal regulation of the human ghrelin receptor gene transcription. Biochem Biophys Res Commun 284:660–666

50. Ramos-Dias JC, Lengyel AM (1999) Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients. Clin Endocrinol 51:461–467

51. Borges JL, Blizzard RM, Gelato MC et al (1983) Effects of human pancreatic tumour growth hormone releasing factor on growth hormone and somatomedin C levels in patients with idiopathic growth hormone deficiency. Lancet 2:119–124

52. Gauna C, Meyler FM, Janssen JAMLJ et al (2004) Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035–5042

53. Muller AF, Janssen JA, Hofland LJ et al (2001) Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab 86:590–593

GHRELIN AND GHRP-6-INDUCED ACTH AND CORTISOL RELEASE IN THYROTOXICOSIS

Estudo 2

Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis

Sergio O. Nascif, Patrícia Molica, Silvia R. Correa-Silva, Marcos R. Silva, Ana-Maria J. Lengyel

Division of Endocrinology, Universidade Federal de São Paulo, UNIFESP/EPM, São Paulo, Brazil

Abbreviated title: Ghrelin and HPA axis in thyrotoxicosis

Keywords: ghrelin, ACTH, cortisol, thyrotoxicosis

Corresponding author:

Sergio de Oliva Nascif

Rua Pedro de Toledo, 910

04039-002 – São Paulo/SP – Brazil

Phone/fax: 55-11-55748432

E-mail: snascif@uol.com.br

Abstract

Thyroid hormones have a role in the regulation of hypothalamic-pituitary-adrenal (HPA) axis, although the mechanisms are still not clear. Ghrelin is a GH-secretagogue and it also increases ACTH and cortisol levels, similarly to GHRP-6, after intravenous administration in humans. The aim of this study was to evaluate the effects of ghrelin and GHRP-6 on ACTH and cortisol levels in 20 hyperthyroid patients due to Graves' disease (mean age: 31 yr; BMI: 23.0 kg/m^2) and in 9 controls (mean age: 29 yr; BMI: 24.1 kg/m^2). Mean basal cortisol (μg/dL) levels were significantly higher in hyperthyroid patients compared to normal subjects (10.7$\pm$0.7 *vs.* 8.1$\pm$0.7). In controls mean AUC cortisol (μg/dL.90min) values after ghrelin injection (1225$\pm$120) were higher than after GHRP-6 (957$\pm$75) and there was a trend to higher peak values after ghrelin administration (16.4$\pm$1.6 *vs.* 13.5$\pm$0.9; *P*=0.055). In patients with hyperthyroidism ghrelin induced a higher cortisol response (peak: 19.1$\pm$0.9; AUC: 1415$\pm$78) than seen after GHRP-6 (15.8$\pm$0.9; 1114$\pm$69). There were no significant differences of cortisol responses to both peptides in terms of peak and AUC between thyrotoxic patients and controls. Similar Δ AUC cortisol values were observed in thyrotoxic patients (ghrelin: 484$\pm$80; GHRP-6: 115$\pm$63) and controls (524$\pm$107; 192$\pm$73). Mean basal ACTH (pg/mL) levels were increased in thyrotoxic patients compared to normal subjects (21.5$\pm$2.9 *vs.*13.5$\pm$1.8). In controls mean peak ACTH and AUC (pg/mL.90min) values after ghrelin administration were 54.9$\pm$10.3 and 2808$\pm$426, respectively. This response was significantly higher than that obtained after GHRP-6 (31.3$\pm$7.9;

1668±265), both in terms of peak ACTH and AUC levels. In thyrotoxicosis mean peak ACTH and AUC values after ghrelin injection (149.7±39.8; 6209±1556) were also significantly higher than after GHRP-6 injection (53.9±11.2; 2767±487). Ghrelin-induced peak ACTH release was increased in hyperthyroid patients when compared to controls and there was a trend in terms of AUC levels (P=0.063). Peak ACTH and AUC values after GHRP-6 in thyrotoxic patients did not reach statistical significance compared to normal subjects. When the Δ AUC values were analyzed, there was a significant increase in ACTH levels after ghrelin in the thyrotoxic group (patients: 4189±1202; controls: 1499±338). After GHRP-6 administration Δ ACTH values in thyrotoxic patients did not reach statistical significance compared to control subjects (patients: 927±330; controls: 539±237). In summary, our results show that cortisol responsiveness to ghrelin and GHRP-6 is normal in thyrotoxicosis. ACTH release after ghrelin is increased, but it does not reach statistical significance with GHRP-6. Our results suggest that the pathways of ACTH release mediated by ghrelin might be activated by thyroid hormone excess, but adrenocortical reserve is maintained.

Introduction

The hypothalamic-pituitary-adrenal (HPA) axis is regulated mainly by corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), which stimulate the release of ACTH and cortisol. However, several neurotransmitters and peptides could have an additional role in the modulation of CRH, AVP and ACTH secretion (Melmed & Kleinberg, 2008).

Thyroid hormones may have a role in the regulation of HPA axis by mechanisms that are not fully elucidated. There is an increase in the production rate of cortisol in thyrotoxicosis because its degradation is accelerated (Levin & Daughaday, 1955; Peterson, 1958; Gordon & Southren, 1977). Thus, in prolonged hyperthyroidism the adrenals secrete at their maximal rate and, depending on the severity/duration of the disease, cortisol responsiveness to different stimuli such as hypoglycemia, ACTH and CRH might be decreased (Jackson *et al.*, 1966; Tsatsoulis *et al.*, 2000; Goswami & Kochupillai, 2001; Yamakita *et al.*, 2001). However, normal cortisol responses to hypoglycemia have also been observed (Jackson *et al.*, 1966; Giustina *et al.*, 1971; Brauman *et al.*, 1973; Moghetti *et al.*, 1994). The impairment of adrenocortical reserve in hyperthyroidism and its normalization after treatment could be due to a decrease in cortisol-binding globulin (CBG) levels, as this globulin is reduced in thyrotoxicosis and returns to normal in the euthyroid state (Dumoulin *et al.*, 1995; Mishra *et al.*, 2007). However, corticosterone in the cerebrospinal fluid and free cortisol index (cortisol/CBG), which reflect free cortisol, are increased in hyperthyroidism (Kamilaris *et al.*, 1991; Johnson *et al.*, 2005; Mishra *et al.*,

2007), suggesting that high circulating cortisol levels are really present and are due to enhanced secretion in this setting.

There are few data in the literature about basal and stimulated ACTH levels in hyperthyroidism. Experimental studies have suggested that thyrotoxicosis is associated with hyperactivity of the HPA axis (Kamilaris *et al.*, 1991; Johnson *et al.*, 2005) and higher basal ACTH levels have been observed in hyperthyroid subjects (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Mishra *et al.*, 2007). It has also been shown that these patients have normal or higher ACTH responsiveness to hypoglycemia or CRH stimulation test (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Lizcano & Salvador, 2008).

Ghrelin, the endogenous ligand of growth hormone secretagogue (GHS) receptor (GHS-R), was discovered in the stomach, but is also present in the hypothalamus, mainly in the arcuate nucleus (Kojima *et al.*, 1999; Gnanapavan *et al.*, 2002; van der Lely *et al.*, 2004). The active form of this peptide is acylated and its chemical structure is different from GHS (Kojima *et al.*, 1999). Ghrelin and GH-releasing peptide-6 (GHRP-6), a GHS, induce GH, ACTH and cortisol release (Arvat *et al.*, 2001; Correa-Silva *et al.*, 2006). Their main site of action is the hypothalamus, as in hypothalamic-pituitary disconnection these effects are reduced or abolished (Popovic *et al.*, 1995; Popovic *et al.*, 2003). A direct adrenal action of these peptides on cortisol release has been suggested as GHS-R mRNA expression was found in this tissue (Gnanapavan *et al.*, 2002), although in much lower concentrations than in the hypothalamic nuclei (Bennett *et al.*, 1997; Guan *et al.*, 1997; Mozid *et al.*, 2003; Korbonits *et al.*, 2004). However, this hypothesis seems unlikely as the effects of ghrelin/GHS on cortisol release are abolished in hypothalamic-pituitary disconnection.

There are no data in the literature about the effect of thyroid hormone excess on ACTH and cortisol release after the administration of ghrelin and GHRP-6. Therefore, the aim of our study was to evaluate ACTH and cortisol responses to ghrelin and GHRP-6 in thyrotoxic patients due to Graves´ disease.

Subjects and methods

Subjects

We studied 20 patients (sixteen women and four men) with hyperthyroidism due to Graves' disease. Their mean age was 31 yr (range: 17 – 44), with a mean body mass index (BMI) of 23.0 kg/m^2 (20.3 – 26.5). All patients had diffuse goiter and/or thyroid ophthalmopathy and had clinical symptoms and signs of thyrotoxicosis. Seven subjects had been previously treated with antithyroid drugs alone or associated with beta-adrenoreceptor blockers and one of them had been previously submitted to radioiodine therapy. The diagnosis of hyperthyroidism was confirmed by high levels of free T4 (7.7$\pm$0.8 ng/mL; mean$\pm$SE; normal range 0.89–1.76), total T3 (644$\pm$50 ng/dL; normal range 60–180), and by suppressed levels of TSH (0.01$\pm$0.01 mU/L; normal range 0.5–5.5). TSH receptor antibody (TRAb) was positive in sixteen patients, varying from 11 to 567 U/L (normal range < 11). None of the patients had other associated diseases and was taking any medication for at least 2 months before the study.

Nine subjects (three women and six men) with no history of thyroid disease were also studied as a control group. Their mean age was 29 yr (range: 20 – 35) and their mean BMI was 24.1 kg/m^2 (20.9 – 25.9). All subjects had normal thyroid function and were free of any medication at the time of the study. The women were tested in the early follicular phase of their menstrual cycle.

Study protocol

The experimental protocol was approved by the ethics committee of Universidade Federal de São Paulo, and all subjects were studied after giving informed consent. The tests were performed after an overnight fast and the subjects remained recumbent throughout it. Each subject underwent two tests, randomly, with an interval of at least 48 h between them. Forty-five minutes before starting the test, an indwelling catheter was inserted into an antecubital vein and kept patent by slow 0.9% saline infusion. After the first blood sample each subject received acylated ghrelin (Neosystem, Strasbourg, France) at a dose of 1 μg/kg or GHRP-6 (Bachem, San Carlos, USA) at a dose of 1 μg/kg, i.v., in bolus. Blood samples were collected every 15 minutes until 90 minutes for subsequent ACTH and cortisol determination. Baseline blood samples were also obtained for free T4, total T3 and TSH. Control subjects were also submitted to the tests using the same procedure as above.

Assays

Serum ACTH was measured by an immunochemiluminometric assay (DPC, Los Angeles, USA). The sensitivity of the method is 5 pg/mL, with mean inter- and intra-assay coefficients of variation of 3.6% and 2.8%, respectively. Serum cortisol levels were measured in duplicate by a fluoroimmunoassay (Wallac Oy, Turku, Finland), with sensitivity of 0.2 μg/dL, and mean inter- and intra-assay coefficients of variation of 8.2% and 6.2%, respectively. Free T4, total T3 and TSH were determined by immunochemiluminometric assays (Advia Centaur, Bayer, USA). TRAb was measured by a radioimmunoassay (RSR Limited, Cardiff, United Kingdom).

Statistical analysis

Friedman's analysis of variance was performed to compare ACTH and cortisol levels after the injection of each peptide. Wilcoxon signed rank test was used for comparisons of ACTH and cortisol values within the same group. Mann-Whitney rank sum test was performed for comparisons between thyrotoxic patients and control subjects. Mean basal levels were calculated using all individual values obtained before the injection of each peptide. The responses were also analyzed by the area under the curve (AUC), which was calculated by trapezoidal integration. Delta (Δ) AUC values subtracting baseline were also calculated when appropriate. The Spearman correlation coefficient was calculated when appropriate. Results are shown as mean $\pm$ SE. $P < 0.05$ was considered statistically significant.

Results

No significant differences in age and BMI were observed in the two study groups.

Mean basal cortisol (μg/dL) levels were significantly higher in hyperthyroid patients (10.7$\pm$0.7) when compared to normal subjects (8.1$\pm$0.7). In control subjects mean AUC cortisol (μg/dL.90min) values after ghrelin injection (1225$\pm$120) were higher than after GHRP-6 (957$\pm$75). In terms of peak levels (Fig. 1), there was a trend to higher values after ghrelin administration (16.4$\pm$1.6 *vs.* 13.5$\pm$0.9; *P*=0.055). In patients with hyperthyroidism ghrelin induced a higher cortisol response (peak: 19.1$\pm$0.9; AUC: 1415$\pm$78) than seen after GHRP-6 (15.8$\pm$0.9; 1114$\pm$69).

When patients with hyperthyroidism were compared to controls, there were no significant differences of cortisol responses to both peptides in terms of peak and AUC. Also, similar Δ AUC cortisol values were observed in thyrotoxic patients (ghrelin: 484$\pm$80; GHRP-6: 115$\pm$63) and controls (524$\pm$107; 192$\pm$73).

Mean basal ACTH (pg/mL) levels were increased in thyrotoxic patients compared to normal subjects (21.5$\pm$2.9 *vs.*13.5$\pm$1.8). In controls mean peak ACTH and AUC (pg/mL.90min) values after ghrelin administration were 54.9$\pm$10.3 and 2808$\pm$426, respectively (Figs. 2 and 3). This response was significantly higher than that obtained after GHRP-6 (31.3$\pm$7.9; 1668$\pm$265), both in terms of peak ACTH and AUC levels. In thyrotoxicosis mean peak ACTH and AUC values after ghrelin injection (149.7$\pm$39.8; 6209$\pm$1556) were also significantly higher than after GHRP-6 injection (53.9$\pm$11.2; 2767$\pm$487).

Ghrelin-induced peak ACTH release was increased in hyperthyroid patients when compared to controls and there was a trend in terms of AUC levels (P=0.063). Peak ACTH and AUC values after GHRP-6 in thyrotoxic patients did not reach statistical significance compared to normal subjects. When the Δ AUC values were analyzed, there was a significant increase in ACTH levels after ghrelin in the thyrotoxic group (patients: 4189$\pm$1202; controls: 1499$\pm$338). After GHRP-6 administration Δ ACTH values in thyrotoxic patients did not reach statistical significance compared to control subjects (patients: 927$\pm$330; controls: 539$\pm$237).

No significant correlations were found between free T4 and other parameters and basal and stimulated cortisol and ACTH values.

Side effects

Hunger sensation, nausea, sleepiness and facial flushing were reported occasionally after ghrelin administration. Facial flushing was the most prominent symptom after GHRP-6 injection.

Fig. 1: Mean peak cortisol levels after ghrelin and GHRP-6 administration in hyperthyroid patients and in control subjects (mean±SE; a, P = 0.055 vs. GHRP-6; b, P < 0.05 vs. GHRP-6).

Fig. 2: Mean ACTH values after ghrelin and GHRP-6 administration in hyperthyroid patients and in control subjects (mean±SE).

Fig. 3: Mean peak ACTH levels after ghrelin and GHRP-6 administration in hyperthyroid patients and in control subjects (mean±SE; a, P < 0.05 vs. GHRP-6).

Discussion

In our study cortisol responsiveness to ghrelin in normal controls and in thyrotoxic patients was higher than seen with GHRP-6. In normal subjects this has been previously described (Correa-Silva *et al.*, 2006) and was also observed with another GHS, hexarelin (Arvat *et al.*, 2001). This could be due to the greater potency of ghrelin in relation to the synthetic analogues (Arvat *et al.*, 2001). It is also possible that ghrelin activates additional pathways to stimulate the HPA axis (Wren *et al.*, 2002; Mozid *et al.*, 2003).

When thyrotoxic patients and controls were compared, no significant differences in terms of peak and AUC cortisol levels were observed between the two study groups, although mean basal cortisol levels were slightly higher in hyperthyroid patients, confirming our previous findings (Molica *et al.*, 2007). Classically, thyroid hormones increase the conversion of cortisol to cortisone. Therefore, the disposal of cortisol is accelerated, but as its rate of secretion is also increased, plasma cortisol concentrations remain normal (Gordon & Southren, 1977; Davies & Larsen, 2008). However, conflicting results about fasting cortisol values have been reported in hyperthyroid patients, with slightly higher (Jackson *et al.*, 1966), normal (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Mishra *et al.*, 2007; Lizcano & Salvador, 2008) or even reduced values compared to normal subjects (Goswami & Kochupillai, 2001). Our finding of slightly higher basal cortisol levels in hyperthyroidism is in agreement with previous reports in humans and also in thyrotoxic rats, which have an increase in circulating corticosterone values, the main glucocorticoid in rodents (Jackson *et al.*, 1966; Johnson *et al.*, 2005). In addition, it has been suggested, in

experimentally-induced hyperthyroidism, that alterations in hypothalamic-pituitary-adrenal function become more pronounced as the duration and severity of thyroid dysfunction increases (Levin & Daughaday, 1955; Johnson *et al.*, 2005), but this information is lacking in thyrotoxic patients. Although there are few data in the literature to allow this analysis, normal plasma cortisol concentrations were found in patients who had lower T4 values (Mishra *et al.*, 2007) compared to our study group. Therefore, although no correlations were found between cortisol and T4 values in our patients, it is possible that differences in duration and/or clinical severity might explain the discrepancies in mean basal cortisol levels in the literature.

The excessive catabolism of cortisol and continuing hyperactivity of the HPA axis in thyrotoxicosis may result in exhaustion of adrenocortical reserve (Gordon & Southren, 1977; Goswami & Kochupillai, 2001). Although controversial, it has been suggested that severely thyrotoxic patients might have an impaired cortisol response to insulin-induced hypoglycemia (Jackson *et al.*, 1966) and to both high and low-dose ACTH stimulation, associated or not with dexamethasone (Tsatsoulis *et al.*, 2000; Goswami & Kochupillai, 2001; Mishra *et al.*, 2007). After normalization of thyroid function this impairment disappears, which suggests that adrenal autoimmune disease is an unlikely cause for the reduced adrenocortical reserve (Goswami & Kochupillai, 2001; Mishra *et al.*, 2007). Moreover, it has been previously shown that in hyperthyroidism there is a significant reduction in CBG (Dumoulin *et al.*, 1995; Mishra *et al.*, 2007), which could decrease serum total cortisol measurements and contribute to these findings. However, our results show that cortisol responsiveness to ghrelin and GHRP-6 is similar in hyperthyroid patients

compared to normal subjects, suggesting that adrenocortical reserve is preserved. This is in agreement with our previous observations (Molica *et al.*, 2007) and also with reports of normal cortisol responsiveness to hypoglycemia and CRH in hyperthyroidism (Giustina *et al.*, 1971; Brauman *et al.*, 1973; Moghetti *et al.*, 1994; Lizcano & Salvador, 2008). It is possible that these different findings are related to the variable clinical features of thyrotoxic patients.

In our study, ghrelin and GHRP-6 were able to release ACTH in normal subjects and in hyperthyroid patients, as previously reported (Frieboes *et al.*, 1995; Arvat *et al.*, 2001; Correa-Silva *et al.*, 2006, Molica *et al.*, 2007). The mean peak and AUC ACTH levels after ghrelin administration were significantly higher than seen after GHRP-6 injection in the two study groups.

Interestingly, we observed an increase in basal ACTH values and also in the ACTH response to ghrelin in thyrotoxicosis compared to normal subjects, which did not reach statistical significance with GHRP-6. It has been previously demonstrated that thyroid hormone excess stimulates the conversion of cortisol to cortisone, which is biologically inactive and unable to inhibit pituitary function (Gordon & Southren, 1977; Davies & Larsen, 2008). Therefore, there is an enhancement in ACTH release, which could explain the increase in basal ACTH values observed by us and by others (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Mishra *et al.*, 2007). Also, ACTH values decrease after treatment in hyperthyroid patients (Yamakita *et al.*, 2001; Mishra *et al.*, 2007). There are few studies in the literature about ACTH responsiveness to stimulation in hyperthyroidism. Normal and higher ACTH responses to hypoglycemia and CRH have been observed both in short- and long-term thyrotoxicosis in humans

and in rats (Moghetti *et al.*, 1994; Yamakita, 2001 *et al.*; Johnson *et al.*, 2005; Lizcano & Salvador, 2008). Some of these studies suggest hyperactivity of HPA axis in hyperthyroidism, which support our findings of enhanced ACTH responsiveness to ghrelin in hyperthyroid patients and also of a decrease in ACTH values after ghrelin, GHRP-6 and CRH with normalization of thyroid function (Molica *et al.*, 2007; Lizcano & Salvador, 2008).

The central mechanisms modulating the increased ACTH release in thyrotoxicosis are still unknown. It is possible that hypothalamic pathways, which are activated by hypoglycemia, and/or pituitary sensitivity to CRH are enhanced in this condition.

It has been shown that the main action of ghrelin/GHS on ACTH/cortisol secretion is exerted at hypothalamic level as these effects are abolished after hypothalamic-pituitary disconnection (Popovic *et al.*, 1995; Popovic *et al.*, 2003). Moreover, GHS are not able to release ACTH in pituitary cells *in vitro* (Elias *et al.*, 1995; Kojima *et al.*, 1999) and normal corticotrophs lack GHS-R (Smith *et al.*, 1997). It has been suggested that HPA activation induced by these peptides probably occurs via stimulation of AVP and/or CRH release. (Thomas *et al.*, 1997; Korbonits *et al.*, 1999a). Reinforcing this hypothesis, it has been shown that GHS-R are located in the paraventricular and arcuate nucleus of the hypothalamus, where AVP, CRH and NPY neurons are found (Bennett *et al.*, 1997; Guan *et al.*, 1997; Korbonits *et al.*, 2004). Experimental studies have shown that GHRP-6 increases mainly AVP release from hypothalamic fragments *in vitro* (Korbonits *et al.*, 1999b), while ghrelin has apparently a broader effect, enhancing AVP, CRH and NPY secretion, with a predominant action on AVP (Wren *et al.*, 2002; Mozid *et al.*, 2003). Although

controversial (Kaji *et al.,* 2001), thyroid hormones enhance the activity of the human GHS-R promoter (Petersenn *et al.*, 2001). Therefore, it is possible that these pathways are activated in thyrotoxicosis, which might explain our findings.

Furthermore, it has been previously suggested that a centrally mediated stimulation of ACTH release is present in hyperthyroidism, which is reinforced by the finding of bilateral increase in the adrenal glands found both in thyrotoxic patients and rats (Goswami & Kochupillai, 2001; Johnson *et al.*, 2005), together with high ACTH and cortisol/corticosterone levels (Moghetti *et al.*, 1994; Yamakita *et al.*, 2001; Johnson *et al.*, 2005; Mishra *et al.*, 2007).

In summary, our results show that cortisol responsiveness to ghrelin and GHRP-6 is normal in thyrotoxicosis. ACTH release after ghrelin is increased, although not reaching statistical significance with GHRP-6. Our results suggest that the pathways of ACTH release mediated by ghrelin might be activated by thyroid hormone excess, but adrenocortical reserve is maintained.

Acknowledgements

References

Altinova AE, Törüner FB, Aktürk M, *et al.* 2006 Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm Res 65:295-299.

Arvat E, Maccario M, di Vito L, *et al.* 2001 Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 86:1169-1174.

Bennett PA, Thomas GB, Howard AD, *et al.* 1997 Hypothalamic growth hormone secretagogue-receptor (GHS-R) expression is regulated by growth hormone in the rat. Endocrinology 138:4552-4557.

Brauman H, Smets P, Corvilain J. 1973 Comparative study of growth response to hypoglycemia in normal subjects and in patients with primary myxedema or hyperthyroidism before and after treatment. J Clin Endocrinol Metab 36:1162-1174.

Correa-Silva SR, Nascif SO, Lengyel AM. 2006 Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH. Pituitary 9:101-107.

Davies TF & Larsen PR. 2008 *Thyrotoxicosis.* In Williams Textbook of Endocrinology (ed. Kronenberg HM), pp. 333-375. Saunders Elsevier, Philadelphia, PA.

Dumoulin SC, Perret BP, Bennet AP, Caron PJ. 1995 Opposite effects of thyroid hormones on binding proteins for steroid hormones (sex hormone-binding globulin and corticosteroid-binding globulin) in humans. Eur J Endocrinol 132:594-598.

Elias KA, Ingle GS, Burnier JP, *et al.* 1995 In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 136:5694-5699.

Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. 1995 Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 61:584-589.

Giménez-Palop O, Giménez-Péres G, Mauricio D, *et al.* 2005 Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur J Endocrinol 153:73-79.

Giustina G, Reschini E, Valentini F, Cantalamessa L. 1971 Growth hormone and cortisol responses to insulin-induced hypoglycemia in thyrotoxicosis. J Clin Endocr 32:571-574.

Gnanapavan S, Kola B, Bustin SA, *et al.* 2002 The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988-2991.

Gordon GG & Southren AL. 1977 Thyroid-hormone effects on steroid-hormone metabolism. Bull N Y Acad Med 53:241-254.

Goswami R & Kochupillai N. 2001 Adrenocortical reserves in patients with Graves' disease. Eur J Endocrinol 144:85.

Guan X, Yu H, Palyha OC, *et al.* 1997 Distribution of mRNA encoding the growth hormone secretagogues receptor in brain and peripheral tissues. Mol Brain Res 48:23-29.

Jackson IMD, Hassan THA, Prentice CRM, Browning MCK. 1966 Insulin-induced hypoglycemia as a test of pituitary-adrenal function in thyrotoxicosis. J Clin Endocr 26:545-549.

Johnson EO, Kamilaris TC, Calogero AE, Gold PW, Chrousos GP. 2005 Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic-pituitary-adrenal axis. Eur J Endocrinol 153:177-185.

Kaji H, Kishimoto M, Kirimura T, *et al.* 2001 Hormonal regulation of the human ghrelin receptor gene transcription. Biochem Biophys Res Commun 284:660-666.

Kamilaris TC, DeBold CR, Johnson EO, *et al.* 1991 Effects of short and long duration hypothyroidism and hyperthyroidism on the plasma adrenocorticotropin and corticosterone responses to ovine corticotropin-releasing hormone in rats. Endocrinology 128:2567-2576.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660.

Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. 2004 Ghrelin – a hormone with multiple functions. Front Neuroendocrinol 25:27-68.

Korbonits M, Kaltsas G, Perry LA, *et al.* 1999a The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 84:2489-2495.

Korbonits M, Little JA, Forsling ML, *et al.* 1999b The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 11:521-528.

Levin ME & Daughaday WH. 1955 The influence of the thyroid on adrenocortical function. J Clin Endocrinol Metab 15:1494-1510.

Lizcano F & Salvador J. 2008 Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol (Epub ahead of print).

Melmed S & Kleinberg D. 2008 *Anterior Pituitary.* In Williams Textbook of Endocrinology (ed. Kronenberg HM), pp. 155-261. Saunders Elsevier, Philadelphia, PA.

Mishra SK, Gupta N, Goswami R. 2007 Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 μg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 92:1693-1696.

Moghetti P, Castello R, Tosi F, *et al.* 1994 Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects. J Clin Endocrinol Metab 78:169-173.

Molica P, Nascif SO, Correa-Silva SR, Silva MR, Sa LBC, Lengyel AMJ. 2007 Increased GHRP-6 and ghrelin-induced ACTH release in thyrotoxicosis. Program of the 89th Annual Meeting of The Endocrine Society, Toronto, Canada, 2007, p348-349 (AbstractP2-89).

Mozid AM, Tringali G, Forsling ML, *et al.* 2003 Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res 35:455-459.

Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM. 2001 Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 142:2649-2659.

Peterson RE. 1958 The influence of the thyroid on adrenal cortical function. J Clin Invest 37:736-743.

Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. 1995 Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 80:942-947.

Popovic V, Miljic D, Micic D, *et al.* 2003 Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 88:3450-3453.

Riis ALD, Hansen TK, Moller N, Weeke J, Jorgensen JOL. 2003 Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab 88:853-857.

Rojdmark S, Calissendorff J, Danielsson O, Brismar K. 2005 Hunger-satiety signals in patients with Graves´ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27:55-61.

Smith RG, Van der Ploeg LH, Howard AD, *et al.* 1997 Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621-645.

Thomas GB, Fairhall KM, Robinson ICAF. 1997 Activation of the hypothalamic-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 138:1585-1591.

Tsatsoulis A, Johnson EO, Kalogera CH, Seferiadis K, Tsolas O. 2000 The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 142:231-235.

van der Lely AJ, Tschop M, Heiman ML, Ghigo E. 2004 Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426-457.

Wren AM, Small CJ, Fribbens CV, *et al.* 2002 The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. Neuroendocrinology 76:316-324.

Yamakita N, Murai T, Kokubo Y, Hayashi M, Akai A, Yasuda K. 2001 Dehydroepiandrosterone sulphate is increased and dehydroepiandrosterone-response to corticotrophin-releasing hormone is decreased in the hyperthyroid state compared with the euthyroid state. Clin Endocrinol 55:797-803.

SUMÁRIO E CONCLUSÕES

SUMÁRIO E CONCLUSÕES

Estudo 1

A ghrelina demonstrou ser um estímulo mais potente do que o GHRP-6 e o GHRH para a secreção de GH em controles e em pacientes com hipertireoidismo. Porém, a resposta do GH após todos os estímulos foi menor na tireotoxicose quando comparada aos indivíduos normais. Portanto, o excesso de hormônios tireoidianos interfere com as vias hipotalâmicas e hipofisárias de liberação de GH ativadas por ghrelina, GHRP-6 e GHRH.

Os valores basais de glicemia dos pacientes com hipertireoidismo não foram significativamente diferentes dos observados em controles. A ghrelina promoveu um aumento similar nas concentrações plasmáticas de glicose em ambos os grupos, enquanto que o GHRP-6 não alterou os níveis circulantes de glicose. Portanto, o excesso de hormônios tireoidianos não interfere nos mecanismos de liberação de glicose estimulados pela ghrelina.

Estudo 2

Foi observado um aumento nos valores basais de ACTH e de cortisol nos pacientes com hipertireoidismo comparado com controles, sugerindo que o excesso de hormônios tireoidianos interfere com o eixo hipotálamo-hipófise adrenal.

A administração da ghrelina promoveu uma liberação maior de ACTH e de cortisol em ambos os grupos, confirmando que a ghrelina é um estímulo potente para ativação do eixo hipotálamo-hipófise adrenal.

A resposta do cortisol à ghrelina e ao GHRP-6 em pacientes com hipertireoidismo foi semelhante a dos controles. A liberação de ACTH após ghrelina na tireotoxicose foi maior que em indivíduos normais, enquanto que com GHRP-6 os valores não alcançaram significância estatística.

Nossos dados sugerem que as vias de liberação de ACTH estimuladas pela ghrelina são ativadas pelo excesso de hormônios tireoidianos, porém sem repercussões significativas na resposta adrenocortical.

ANEXOS – Estudo 1

Tabela 1 – Dados clínicos dos indivíduos normais.

Indivíduo	Sexo	Idade (anos)	IMC (kg/m^2)*
1	M	28	25,7
2	M	36	19,5
3	M	28	23,3
4	M	30	22,4
5	M	30	25,5
6	F	34	20,9
7	F	35	23,7
8	F	20	24,3
Média		30,1	23,2
DP		5,1	2,2
EP		1,8	0,8

* IMC = índice de massa corpórea

Tabela 2 – Dados laboratoriais dos indivíduos normais.

Indivíduo	T3 total (ng/dL)[a]	T4 livre (ng/mL)[b]	TSH (mU/L)[c]
1	103	1,1	2,0
2	123	1,3	1,1
3	115	1,1	1,5
4	121	1,3	1,3
5	111	1,1	0,6
6	118	1,1	1,3
7	156	1,1	2,4
8	126	1,1	3,0
Média	121,6	1,2	1,7
DP	15,7	0,1	0,8
EP	5,5	0,03	0,3

a. Valor normal: 60 – 180

b. Valor normal: 0,89 – 1,76

c. Valor normal: 0,5 – 5,5

Tabela 3 – Dados clínicos dos pacientes com hipertireoidismo.

Indivíduo	Sexo	Idade (anos)	IMC* (kg/m²)	Tratamento prévio
1	F	34	23,1	Sim
2	F	26	22,1	Não
3	F	44	20,3	Não
4	F	27	24,4	Sim
5	F	36	26,5	Não
6	F	28	24,7	Sim
7	F	36	23,3	Não
8	M	31	20,5	Não
9	F	42	22,4	Não
10	M	28	20,8	Não
Média		33,2	22,8	
DP		6,3	2,0	
EP		2,0	0,6	

* IMC = índice de massa corpórea

Tabela 4 – Valores individuais e níveis médios de T3 total, T4 livre, TSH e TRAb nos pacientes com hipertireoidismo.

Indivíduo	T3 total (ng/dL)[a]	T4 livre (ng/mL)[b]	TSH (mU/L)[c]	TRAb (U/L)[d]
1	316	4,2	< 0,01	94,0
2	> 800	9,9	< 0,01	300,0
3	> 800	> 12,0	< 0,01	< 11,0
4	785	11,4	< 0,01	< 11,0
5	247	2,7	< 0,01	< 11,0
6	285	2,7	0,1	15,0
7	> 800	> 12,0	< 0,01	45,0
8	332	3,5	< 0,01	11,0
9	> 800	9,0	< 0,01	58,0
10	680	6,6	< 0,01	233,7
Média	584,5	7,4	0,02	
DP	252,7	3,9	0,03	
EP	79,9	1,2	0,01	

a. Valor normal: 60 – 180

b. Valor normal: 0,89 – 1,76

c. Valor normal: 0,5 – 5,5

d. Valor normal: < 11,0

Tabela 5 – Valores individuais e níveis médios de GH após a administração de ghrelina (1 μg/kg), ev, em 8 indivíduos normais.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,03	70,4	110,4	80,8	57,3	52,7	40,8	25,4	14,2
2	0,2	7,3	50,8	65,8	45,8	25,4	13,5	6,9	3,7
3	0,02	37,5	95,8	90,4	57,3	33,1	41,1	23,9	15,3
4	0,2	35,2	43,5	29,0	19,3	14,4	8,6	4,8	3,0
5	0,02	17,5	25,1	18,5	10,4	8,5	6,0	4,2	2,7
6	0,08	16,8	41,9	32,4	21,2	13,0	6,4	5,2	2,3
7	0,07	23,0	27,9	17,0	7,0	3,7	2,5	1,0	0,6
8	0,06	78,1	123,5	102,3	80,8	53,1	34,1	16,9	11,6
Média	0,09	35,7	64,9	54,5	37,4	25,5	19,1	11,0	6,7
DP	0,07	25,8	38,9	34,3	26,7	19,3	16,6	9,6	6,0
EP	0,03	9,1	13,8	12,1	9,4	6,8	5,9	3,4	2,1

Tabela 6 – Valores individuais e níveis médios de GH após a administração de GHRP-6 (1 μg/kg), ev, em 8 indivíduos normais.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,4	23,8	35,5	25,8	17,9	11,9	7,1	3,8	2,3
2	0,13	11,6	14,2	8,4	4,2	2,4	1,0	0,5	0,3
3	0,04	12,1	29,1	26,3	15,8	8,9	4,7	2,6	1,4
4	0,07	19,5	24,7	17,9	9,2	4,8	2,4	1,5	1,2
5	0,01	13,3	17,7	15,9	11,8	6,7	2,4	1,2	0,8
6	0,7	11,0	25,2	19,3	12,7	6,9	3,7	2,1	1,1
7	0,2	6,2	10,6	9,6	4,3	3,0	2,3	2,0	1,4
8	0,16	34,6	56,5	51,5	37,3	28,6	15,4	8,8	4,3
Média	0,21	16,5	26,7	21,8	14,2	9,2	4,9	2,8	1,6
DP	0,23	9,1	14,5	13,6	10,6	8,4	4,6	2,6	1,2
EP	0,08	3,2	5,1	4,8	3,7	3,0	1,6	0,9	0,4

Tabela 7 – Valores individuais e níveis médios de GH após a administração de GHRH (100 μg), ev, em 8 indivíduos normais.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,03	15,8	19,3	28,8	37,6	38,5	30,8	18,7	11,0
2	0,04	3,4	3,6	2,2	2,3	1,8	1,2	0,8	0,8
3	0,03	8,3	9,2	6,8	7,5	7,3	5,7	3,8	2,4
4	0,03	6,2	5,0	4,0	3,5	2,7	2,2	1,4	1,1
5	0,01	3,9	4,8	5,4	4,4	3,2	1,9	1,2	0,6
6	0,06	7,5	8,1	6,6	4,8	2,4	1,4	0,8	0,4
7	0,13	16,0	21,5	24,8	22,6	19,8	13,7	18,2	13,8
8	0,6	8,0	8,1	11,0	8,2	9,4	12,5	7,1	5,3
Média	0,12	8,6	10,0	11,2	11,4	10,6	8,7	6,5	4,4
DP	0,2	4,8	6,8	10,0	12,4	12,7	10,2	7,7	5,2
EP	0,07	1,7	2,4	3,5	4,4	4,5	3,6	2,7	1,8

Tabela 8 – Valores individuais e níveis médios de GH após a administração de ghrelina (1 μg/kg), ev, em 10 pacientes com hipertireoidismo.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,2	12,9	13,3	8,3	4,1	1,9	1,1	0,7	0,4
2	1,2	31,5	18,2	12,7	8,0	4,3	2,6	1,5	1,3
3	1,4	18,3	11,0	6,4	4,8	3,0	2,5	2,0	1,5
4	1,2	24,2	14,4	7,0	5,0	3,0	2,1	1,3	0,9
5	0,1	28,4	25,1	15,9	9,6	5,4	2,8	1,8	1,1
6	0,1	7,8	9,6	5,6	3,0	1,4	0,7	0,4	0,2
7	0,5	13,7	13,0	10,8	6,0	4,7	2,9	1,8	1,2
8	2,2	25,3	17,7	13,2	9,2	8,1	6,5	4,4	3,6
9	0,3	17,0	10,2	6,8	2,9	4,5	2,2	1,6	1,3
10	1,5	11,9	7,0	4,8	4,5	4,7	5,0	5,5	4,9
Média	0,9	19,1	14,0	9,2	5,7	4,1	2,8	2,1	1,6
DP	0,7	7,9	5,2	3,8	2,4	1,9	1,7	1,6	1,5
EP	0,2	2,5	1,7	1,2	0,8	0,6	0,5	0,5	0,5

Tabela 9 – Valores individuais e níveis médios de GH após a administração de GHRP-6 (1 μg/kg), ev, em 10 pacientes com hipertireoidismo.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,6	19,7	16,4	11,8	8,7	5,6	3,7	2,3	1,3
2	1,9	15,3	11,3	9,0	8,4	5,8	3,5	2,7	2,3
3	1,1	9,9	9,0	6,1	4,1	2,5	1,9	1,3	1,4
4	0,7	13,3	8,9	5,7	3,5	2,2	1,4	1,0	0,8
5	0,2	15,7	9,9	6,1	3,0	0,7	0,6	0,8	0,4
6	0,1	6,8	3,8	2,5	1,7	1,3	0,7	0,3	0,2
7	0,7	8,3	6,3	3,7	2,4	1,7	0,8	0,5	0,5
8	0,6	17,0	11,1	8,7	7,2	5,9	5,4	4,4	4,1
9	0,1	10,6	10,6	7,4	5,8	3,8	3,4	3,3	2,8
10	0,5	9,7	8,1	7,7	6,4	5,3	4,5	3,6	3,3
Média	0,7	12,6	9,5	6,9	5,1	3,5	2,6	2,0	1,7
DP	0,5	4,2	3,3	2,7	2,5	2,0	1,7	1,4	1,3
EP	0,2	1,3	1,1	0,8	0,8	0,6	0,5	0,5	0,4

Tabela 10 – Valores individuais e níveis médios de GH após a administração de GHRH (100 μg), ev, em 10 pacientes com hipertireoidismo.

	GH (μg/L)								
	Tempo (min)								
Indiv.	**0**	**15**	**30**	**45**	**60**	**75**	**90**	**105**	**120**
1	0,2	1,0	2,1	2,5	3,6	4,3	4,1	4,2	3,5
2	1,3	4,0	3,8	3,7	4,8	5,7	6,3	5,7	4,3
3	2,3	3,9	3,3	3,3	2,8	2,9	3,1	2,8	3,3
4	1,1	2,6	2,4	2,6	3,2	3,7	3,3	3,3	2,9
5	0,1	1,5	1,4	2,7	4,0	4,4	3,1	1,6	1,0
6	1,2	10,7	9,4	9,6	11,5	10,6	10,7	9,9	8,8
7	0,6	2,9	2,5	2,1	1,9	2,3	2,1	2,5	2,0
8	0,3	3,6	4,0	3,9	3,9	5,8	6,7	6,3	5,7
9	1,0	2,9	3,0	2,5	2,0	2,0	2,7	3,2	2,7
10	0,7	3,5	2,7	2,5	3,5	4,5	5,1	5,9	5,7
Média	0,9	3,7	3,5	3,4	4,1	4,6	4,7	4,5	4,0
DP	0,7	2,7	2,2	2,2	2,7	2,4	2,6	2,5	2,3
EP	0,2	0,8	0,7	0,7	0,9	0,8	0,8	0,8	0,7

Tabela 11 – Valores individuais e níveis médios do pico de GH e da área sob a curva após a administração de ghrelina (1 μg/kg), GHRP-6 (1 μg/kg) ou GHRH (100 μg), ev, em 8 indivíduos normais.

Indiv.	Pico GH (μg/L)			ASC (μg/L.120min)		
	Ghrelina	GHRP-6	GHRH	Ghrelina	GHRP-6	GHRH
1	110,4	35,5	38,5	6674	1907	2925
2	65,8	14,2	3,6	3262	638	236
3	95,8	29,1	9,2	5802	1503	747
4	43,5	24,7	6,2	2346	1210	383
5	25,1	17,7	5,4	1373	1041	377
6	41,9	25,2	8,1	2071	1227	477
7	27,9	10,6	24,8	1237	582	2153
8	123,5	56,5	12,5	7419	3524	1009
Média	66,7	26,7	13,5	3773	1454	1038
DP	38,5	14,5	12,1	2485	941	979
EP	13,6	5,1	4,3	878	333	346

Tabela 12 – Valores individuais e níveis médios do pico de GH e da área sob a curva após a administração de ghrelina (1 μg/kg), GHRP-6 (1 μg/kg) ou GHRH (100 μg), ev, em 10 pacientes com hipertireoidismo.

Indiv.	Pico GH (μg/L)			ASC (μg/L.120min)		
	Ghrelina	GHRP-6	GHRH	Ghrelina	GHRP-6	GHRH
1	13,3	19,7	4,3	639	1037	355
2	31,5	15,3	6,3	1201	872	552
3	18,3	9,9	3,9	742	541	374
4	24,2	13,3	3,7	871	551	346
5	28,4	15,7	4,4	1344	557	289
6	9,6	6,8	11,5	430	259	1161
7	13,7	8,3	2,9	806	365	264
8	25,3	17,0	6,7	1310	931	559
9	17,0	10,6	3,2	690	695	302
10	11,9	9,7	5,9	695	708	464
Média	19,3	12,6	5,3	873	652	467
DP	7,6	4,2	2,5	309	247	265
EP	2,4	1,3	1,3	98	78	84

Tabela 13 – Valores individuais e níveis médios de glicemia (mg/dL) após a administração de ghrelina (1 μg/kg), ev, em 8 indivíduos normais.

	Glicemia (mg/dL)				
	Tempo (min)				
Indiv.	**0**	**30**	**60**	**90**	**120**
1	85	99	89	90	92
2	80	88	84	87	86
3	81	86	83	75	85
4	84	91	94	90	93
5	82	86	85	89	92
6	73	77	75	75	75
7	84	90	89	86	86
8	81	90	85	90	87
Média	81,3	88,4	85,5	85,3	87,0
DP	3,8	6,2	5,6	6,5	5,8
EP	1,3	2,2	2,0	2,3	2,1

Tabela 14 – Valores individuais e níveis médios de glicemia (mg/dL) após a administração de GHRP-6 (1 μg/kg), ev, em 8 indivíduos normais.

	Glicemia (mg/dL)				
	Tempo (min)				
Indiv.	0	30	60	90	120
1	86	91	90	86	100
2	93	93	93	92	95
3	88	86	82	85	84
4	88	93	93	97	93
5	85	89	88	91	93
6	75	73	75	77	78
7	82	82	83	83	84
8	86	88	85	85	84
Média	85,4	86,9	86,1	87,0	88,9
DP	5,2	6,7	6,2	6,2	7,4
EP	1,9	2,4	2,2	2,2	2,6

Tabela 15 – Valores individuais e níveis médios de glicemia (mg/dL) após a administração de ghrelina (1 μg/kg), ev, em 10 pacientes com hipertireoidismo.

	Glicemia (mg/dL)				
	Tempo (min)				
Indiv.	**0**	**30**	**60**	**90**	**120**
1	84	89	91	90	86
2	82	91	89	87	85
3	64	71	71	70	71
4	92	109	100	98	92
5	95	96	95	94	97
6	87	95	94	91	89
7	88	98	93	93	83
8	95	98	96	97	95
9	81	85	83	81	76
10	83	101	90	85	84
Média	85,1	93,3	90,2	88,6	85,8
DP	9,0	10,3	8,1	8,4	8,1
EP	2,9	3,2	2,6	2,7	2,6

Tabela 16 – Valores individuais e níveis médios de glicemia (mg/dL) após a administração de GHRP-6 (1 μg/kg), ev, em 10 pacientes com hipertireoidismo.

	Glicemia (mg/dL)				
	Tempo (min)				
Indiv.	**0**	**30**	**60**	**90**	**120**
1	82	84	83	84	83
2	-	-	-	-	-
3	88	85	79	75	73
4	95	100	99	97	94
5	91	92	91	92	92
6	96	96	93	90	90
7	101	102	102	104	110
8	85	93	89	91	90
9	87	87	85	85	81
10	94	100	97	97	96
Média	91,0	93,2	90,9	90,6	89,9
DP	6,0	6,8	7,7	8,5	10,5
EP	2,0	2,3	2,6	2,8	3,5

Tabela 17 – Valores individuais e níveis médios do pico de glicemia e da área sob a curva após a administração de ghrelina (1 μg/kg) ou GHRP-6 (1 μg/kg), ev, em 8 indivíduos normais.

Indiv.	Pico glicemia (mg/dL)		ASC (mg/dL.120min)	
	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	99	100	10995	10800
2	88	95	10260	11160
3	86	86	9810	10170
4	94	97	10905	11205
5	92	93	10410	10710
6	77	78	9030	9045
7	90	84	10500	9930
8	90	88	10470	10290
Média	89,5	90,1	10298	10414
DP	10,7	7,4	631	717
EP	3,8	2,6	223	254

Tabela 18 – Valores individuais e níveis médios do pico de glicemia e da área sob a curva após a administração de ghrelina (1 μg/kg) ou GHRP-6 (1 μg/kg), ev, em 10 pacientes com hipertireoidismo.

	Pico glicemia (mg/dL)		ASC (mg/dL.120min)	
Indiv.	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	91	84	10650	10005
2	91	-	10515	-
3	71	85	8385	9585
4	109	100	11970	11715
5	97	92	11430	10995
6	95	96	11040	11160
7	98	110	11085	12405
8	98	93	11580	11115
9	85	87	9825	10230
10	101	100	10785	11670
Média	93,6	94,1	10727	10987
DP	10,2	8,4	1019	905
EP	3,2	2,8	322	302

ANEXOS – Estudo 2

Tabela 1 – Dados clínicos do grupo controle.

Indivíduo	Sexo	Idade (anos)	IMC (kg/m^2)*
1	M	28	25,7
2	M	28	23,3
3	M	30	22,4
4	M	30	25,5
5	F	34	20,9
6	F	35	23,7
7	F	20	24,3
8	M	26	24,9
9	M	28	25,9
Média		28,8	24,1
DP		4,4	1,7
EP		1,5	0,6

* IMC = índice de massa corpórea

Tabela 2 – Valores individuais e níveis médios das dosagens basais do grupo controle.

Indivíduo	TSH (mU/L)[a]	ACTH (pg/mL)[b]	Cortisol (µg/dL)[c]
1	2,0	7,3	9,7
2	1,5	27,6	12
3	1,3	7,7	10,1
4	0,6	8,1	8,7
5	1,3	14,4	7,4
6	2,4	8,5	4,7
7	3,0	9,6	7,5
8	1,3	22,2	8,4
9	1,2	16,6	5,1
Média	1,6	13,6	8,2
DP	0,7	7,3	2,3
EP	0,2	2,4	0,8

a. Valor normal: 0,5 – 5,5

b. Valor normal: até 46,0

c. Valor normal: 7,0 – 25,0

Tabela 3 – Dados clínicos dos pacientes com hipertireoidismo.

Indivíduo	Sexo	Idade (anos)	IMC* (kg/m²)	Tratamento prévio
1	F	34	23,1	Sim
2	F	26	22,1	Não
3	F	44	20,3	Não
4	F	27	24,4	Sim
5	F	36	26,5	Não
6	F	28	24,7	Sim
7	F	36	23,3	Não
8	M	31	20,5	Não
9	F	42	22,4	Não
10	M	28	20,8	Não
11	F	38	25,5	Sim
12	F	26	24,8	Sim
13	F	17	24,0	Não
14	F	31	23,2	Não
15	M	32	24,7	Não
16	F	22	21,5	Não
17	M	25	22,3	Não
18	F	42	21,3	Sim
19	F	31	22,2	Não
20	F	22	21,5	Sim
Média		30,9	23,0	
DP		7,2	1,8	
EP		1,6	0,4	

* IMC = índice de massa corpórea

Tabela 4 – Valores individuais e níveis médios das dosagens basais nos pacientes com hipertireoidismo.

Indivíduo	T3 (ng/dL)[a]	T4 livre (ng/mL)[b]	TSH (mU/L)[c]	TRAb (U/L)[d]
1	316,0	4,2	< 0,01	94,0
2	> 800,0	9,9	< 0,01	300,0
3	> 800,0	> 12,0	< 0,01	< 11,0
4	784,6	11,4	< 0,01	< 11,0
5	246,8	2,7	< 0,01	< 11,0
6	284,5	2,7	0,1	15,0
7	> 800,0	> 12,0	< 0,01	45,0
8	332,2	3,5	< 0,01	11,0
9	> 800,0	9,0	< 0,01	58,0
10	680,0	6,6	< 0,01	233,7
11	494,2	5,9	< 0,01	51,6
12	> 800,0	> 12,0	< 0,01	567,0
13	> 800,0	10,0	< 0,01	> 405,0
14	> 800,0	8,8	< 0,01	233,6
15	679,3	7,8	< 0,01	33,5
16	> 800,0	9,0	< 0,01	< 11,0
17	> 800,0	4,7	< 0,01	14,4
18	265,6	2,8	< 0,01	59,7
19	> 800,0	7,7	< 0,01	268,8
20	> 800,0	> 12,0	< 0,01	> 405,0
Média	644,2	7,7	0,01	
DP	223,3	3,4	0,02	
EP	49,9	0,8	0,01	

a. Valor normal: 60 – 180

b. Valor normal: 0,89 – 1,76

c. Valor normal: 0,5 – 5,5

d. Valor normal: até 11,0

Tabela 5 – Valores individuais e níveis médios de cortisol após administração de ghrelina em controles.

	Cortisol (µg/dL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	8,4	16,3	23,8	23,2	22,2	19,1
2	9,6	12,2	15,2	14,9	14,1	13,6
3	7,3	10,2	16,4	18,1	17,9	12,7
4	9,2	15,2	17,7	20,1	19,6	17,3
5	9,6	10,6	12,5	10,2	9,4	8,5
6	6,3	8,6	10,7	9,3	7,6	7,5
7	7,5	21,5	18,8	17,7	16,7	14,8
8	6,9	11,3	14,9	14,2	11,4	8,4
9	5,3	9,1	11,0	9,4	11,2	7,8
Média	7,8	12,8	15,7	15,2	14,5	12,2
DP	1,5	4,2	4,2	5,0	4,9	4,4
EP	0,5	1,4	1,4	1,7	1,7	1,5

Tabela 6 – Valores individuais e níveis médios de cortisol após administração de GHRP-6 em controles.

	Cortisol (μg/dL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	10,9	13,3	16,2	16,3	12,7	10,6
2	14,3	15,6	15,7	16,8	13,6	13,0
3	12,9	12,5	11,6	10,6	9,6	7,5
4	8,2	12,6	11,7	10,3	9,5	8,0
5	5,1	10,3	8,8	6,6	5,9	6,9
6	3,0	9,0	7,1	6,3	7,7	7,8
7	7,4	11,2	12,9	15,3	12,0	9,1
8	9,8	12,7	11,4	10,4	9,0	7,8
9	4,9	15,6	12,2	11,5	9,0	7,2
Média	8,5	12,5	12,0	11,6	9,9	8,7
DP	3,8	2,2	2,9	3,9	2,5	2,0
EP	1,3	0,7	1,0	1,3	0,8	0,7

Tabela 7 – Valores individuais e níveis médios de ACTH após a administração de ghrelina em controles.

	ACTH (pg/mL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	7,6	66,1	42,4	30,2	25,0	12,4
2	33,4	67,1	58,9	47,4	38,1	25,4
3	5,0	21,4	32,4	25,1	16,5	5,0
4	9,5	60,0	57,5	33,4	26,3	13,5
5	15,7	21,9	19,6	16,5	12,8	11,9
6	10,0	19,2	21,4	16,2	14,0	11,0
7	11,1	30,3	28,3	21,5	16,5	9,6
8	23,6	82,6	68,6	51,6	34,7	20,5
9	15,0	112,0	74,2	48,5	30,5	14,2
Média	14,5	53,4	44,8	32,4	23,8	13,7
DP	8,9	32,4	20,6	13,9	9,4	6,0
EP	3,0	10,8	6,9	4,6	3,1	2,0

Tabela 8 – Valores individuais e níveis médios de ACTH após a administração de GHRP-6 em controles.

	ACTH (pg/mL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	6,9	49,4	29,4	19,9	15,3	9,6
2	21,8	27,3	22,0	18,9	17,1	14,9
3	10,4	10,8	8,5	7,0	7,8	7,6
4	6,7	13,6	12,8	10,4	7,7	6,5
5	13,1	21,0	16,5	14,0	13,2	19,0
6	7,0	20,0	15,0	14,5	16,4	19,0
7	8,1	24,0	18,3	15,0	13,0	11,0
8	20,8	28,9	22,6	19,0	16,8	14,6
9	18,1	87,1	56,1	34,1	21,7	12,5
Média	12,5	31,3	22,4	17,0	14,3	12,7
DP	6,2	23,7	14,0	7,7	4,5	4,5
EP	2,1	7,9	4,7	2,6	1,5	1,5

Tabela 9 – Valores individuais e níveis médios de cortisol após a administração de ghrelina em pacientes com hipertireoidismo.

	Cortisol (μg/dL)					
	Tempo (min)					
Indiv.	0	15	30	45	60	90
1	9,9	19,8	20,5	22,1	21,6	17,4
2	2,5	11,3	15,4	18,4	19,0	16,5
3	12,5	21,6	22,7	26,1	28,0	27,9
4	8,4	14,5	14,1	12,1	9,4	4,8
5	8,6	16,1	18,8	20,1	16,8	12,8
6	7,0	12,1	16,1	17,3	14,8	11,7
7	10,1	16,5	19,4	10,3	18,3	12,7
8	7,5	16,5	22,3	21,5	18,6	13,1
9	14,9	12,4	13,9	12,6	10,4	10,8
10	16,7	20,7	21,3	22,8	23,4	21,5
11	7,6	13,9	16,4	17,9	16,6	11,5
12	8,8	13,8	14,9	15,9	13,5	9,1
13	7,4	12,4	13,3	13,5	9,4	5,1
14	13,5	17,1	18,3	15,9	17,3	8,0
15	18,6	20,4	20,9	22,4	21,9	15,9
16	6,4	10,8	14,2	14,9	18,2	9,7
17	6,8	11,5	14,5	14,6	10,9	6,7
18	20,7	22,6	24,9	21,3	17,9	11,0
19	11,9	16,0	19,4	20,1	21,6	15,1
20	7,1	9,9	14,3	14,7	13,2	11,2
Média	10,3	15,5	17,8	17,7	17,0	12,6
DP	4,6	3,9	3,5	4,2	5,0	5,5
EP	1,0	0,9	0,8	1,2	1,1	1,2

Tabela 10 – Valores individuais e níveis médios de cortisol após a administração de GHRP-6 em pacientes com hipertireoidismo.

	Cortisol (μg/dL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	15,7	18,5	15,2	11,7	10,3	7,2
2	5,9	11,7	15,3	16,4	16,0	11,1
3	11,0	17,1	15,0	11,8	9,9	13,0
4	9,3	13,5	12,6	10,7	11,0	6,5
5	9,7	15,4	12,6	10,5	7,9	6,7
6	11,2	10,9	8,9	7,7	6,9	6,7
7	6,3	10,7	10,0	8,6	10,2	10,4
8	9,2	19,9	22,0	17,7	15,7	11,3
9	10,8	12,1	12,1	11,3	10,0	9,8
10	15,6	17,8	20,7	20,7	19,0	14,2
11	12,3	14,7	16,9	14,5	13,2	19,2
12	10,6	15,4	16,0	14,8	16,3	10,1
13	6,2	11,7	13,9	12,2	10,5	6,5
14	13,5	15,1	15,6	13,6	10,9	5,8
15	12,7	14,7	13,8	11,5	9,6	11,5
16	11,6	13,7	13,6	8,8	7,1	7,6
17	15,2	20,1	21,5	18,4	14,6	9,5
18	11,7	16,9	17,7	15,4	11,5	7,2
19	20,2	21,1	20,6	15,2	14,5	8,7
20	3,3	5,7	4,0	2,7	2,7	1,0
Média	11,1	14,8	14,9	12,7	11,4	9,2
DP	3,9	3,8	4,4	4,2	3,9	3,8
EP	0,9	0,8	1,0	0,9	0,9	0,8

Tabela 11 – Valores individuais e níveis médios de ACTH após administração de ghrelina em pacientes com hipertireoidismo.

	ACTH (pg/mL)					
	Tempo (min)					
Indiv.	0	15	30	45	60	90
1	19,4	98,6	74,6	57,4	48,7	27,5
2	6,7	181,0	146,0	80,2	45,4	28,7
3	20,0	336,0	205,0	120,0	87,2	61,4
4	13,6	74,7	57,1	25,0	17,7	10,1
5	10,8	44,0	47,1	24,7	18,3	12,3
6	7,0	23,0	28,5	18,9	12,1	5,8
7	13,1	140,0	100,0	64,0	33,2	19,0
8	12,0	130,0	78,3	54,0	32,0	18,0
9	5,2	67,5	52,0	41,0	23,0	16,4
10	94,2	817,0	559,0	349,0	225,0	90,8
11	12,2	103,0	60,1	36,3	23,4	12,0
12	20,4	160,0	105,0	67,8	42,9	26,1
13	9,6	28,4	18,2	15,4	11,0	8,3
14	23,0	62,5	45,0	33,7	24,4	16,5
15	71,3	287,0	152,0	91,7	61,3	28,1
16	11,1	50,6	53,9	40,0	25,2	16,4
17	12,9	52,9	45,8	32,1	22,2	13,9
18	61,8	202,0	118,0	66,7	30,0	15,5
19	12,7	66,4	61,7	39,9	27,1	16,2
20	12,0	58,3	47,9	37,6	29,4	18,9
Média	22,5	149,1	102,8	64,8	42,0	23,1
DP	24,1	178,3	117,1	71,9	46,7	19,8
EP	5,4	39,9	26,2	16,1	10,4	4,4

Tabela 12 – Valores individuais e níveis médios de ACTH após administração de GHRP-6 em pacientes com hipertireoidismo.

	ACTH (pg/mL)					
	Tempo (min)					
Indiv.	**0**	**15**	**30**	**45**	**60**	**90**
1	13,3	16,6	12,3	11,3	7,4	8,1
2	12,3	121,0	92,4	64,8	46,3	25,9
3	13,5	41,7	29,3	22,7	17,1	24,9
4	16,8	44,9	27,7	23,2	22,2	12,7
5	14,0	19,5	16,1	12,4	10,2	8,5
6	12,5	12,6	10,3	9,1	10,1	9,0
7	9,0	14,3	14,5	16,0	15,6	16,0
8	18,5	81,5	45,0	35,0	26,0	15,0
9	23,0	55,3	45,0	33,0	29,0	22,0
10	60,2	222,0	155,0	96,0	84,7	57,8
11	23,7	49,6	32,5	25,8	20,1	18,7
12	20,8	60,7	49,5	41,9	39,4	27,8
13	13,1	23,8	25,2	21,5	14,8	11,2
14	23,6	31,6	25,6	23,1	17,4	14,0
15	26,5	32,3	27,5	22,9	20,4	22,2
16	15,7	30,4	19,9	14,1	18,3	14,4
17	29,7	112,0	61,9	40,2	24,8	14,8
18	29,5	59,7	51,8	38,3	29,0	18,6
19	25,8	34,8	22,1	14,4	11,3	10,5
20	7,5	10,4	8,3	7,9	6,2	6,9
Média	20,5	53,7	38,6	28,7	23,5	18,0
DP	11,5	50,1	34,2	21,1	17,6	11,2
EP	2,6	11,2	7,6	4,7	3,9	2,5

Tabela 13 – Resposta do cortisol expressa em pico e ASC após administração de ghrelina e GHRP-6 em controles.

Indiv.	Pico (μg/dL)		ASC (μg/dL.90min)	
	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	23,8	16,3	1799	1214
2	15,2	16,8	1258	1330
3	18,1	12,9	1319	946
4	20,1	12,6	1565	914
5	12,5	10,3	911	660
6	10,7	9,0	760	649
7	21,5	15,3	1524	1053
8	14,9	12,7	1040	911
9	11,2	15,6	851	937
Média	16,4	13,5	1225	957
DP	4,7	2,7	359	224
EP	1,6	0,9	120	75

Tabela 14 – Resposta do ACTH expressa em pcio e ASC após administração de ghrelina e GHRP-6 em controles.

Indiv.	Pico (pg/mL)		ASC (pg/mL.90min)	
	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	66,1	49,4	2886	2021
2	67,1	27,3	4090	1795
3	32,4	10,8	1667	762
4	60,0	13,6	3128	873
5	21,9	21,0	1454	1453
6	21,4	20,0	1407	1449
7	30,3	24,0	1800	1378
8	82,6	28,9	4307	1811
9	112,0	87,1	4532	3471
Média	54,9	31,3	2808	1668
DP	30,9	23,7	1279	794
EP	10,3	7,9	426	265

Tabela 15 – Resposta do cortisol expressa em pico e ASC após administração de grhelina e GHRP-6 em pacientes com hipertireoidismo.

Indiv.	Pico (µg/dL)		ASC (µg/dL.90min)	
	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	22,1	18,5	1757	1139
2	19,0	16,4	1370	1222
3	28,0	17,1	2198	1159
4	14,5	13,5	957	967
5	20,1	15,4	1460	929
6	17,3	10,9	1244	752
7	19,4	10,7	1371	872
8	22,3	22,0	1576	1486
9	13,9	12,1	1091	986
10	23,4	20,7	1946	1646
11	17,9	19,2	1326	1369
12	15,9	16,3	1175	1291
13	13,5	13,9	932	947
14	18,3	15,6	1380	1098
15	22,4	14,7	1826	1084
16	18,2	13,7	1202	902
17	14,6	21,5	1006	1485
18	24,9	17,7	1755	1205
19	21,6	21,1	1634	1462
20	14,7	5,7	1102	287
Média	19,1	15,8	1415	1114
DP	4,0	4,2	350	309
EP	0,9	0,9	78	69

Tabela 16 – Resposta do ACTH expressa em pico e ASC após administração de ghrelina e GHRP-6 em pacientes com hipertireoidismo.

Indiv.	Pico (pg/mL)		ASC (pg/mL.90min)	
	Ghrelina	GHRP-6	Ghrelina	GHRP-6
1	98,6	16,6	5113	991
2	181,0	121,0	7610	5696
3	336,0	41,7	12948	2265
4	74,7	44,9	3004	2253
5	47,1	19,5	2414	1182
6	28,5	12,6	1468	936
7	140,0	16,0	5690	1331
8	130,0	81,5	5015	3371
9	67,5	55,3	3210	3155
10	817,0	222,0	33006	10319
11	103,0	49,6	3789	2529
12	160,0	60,7	6502	3741
13	28,4	25,2	1374	1657
14	62,5	31,6	3087	1983
15	287,0	32,3	10296	2231
16	53,9	30,4	3064	1712
17	52,9	112,0	2767	4214
18	202,0	59,7	7172	3400
19	66,4	34,8	3468	1675
20	58,3	10,4	3192	698
Média	149,7	53,9	6209	2767
DP	178,0	50,0	6957	2176
EP	39,8	11,2	1556	487

Tabela 17 – Resposta do cortisol expressa em Δ ASC após administração de ghrelina e GHRP-6 em controles.

Indiv.	Δ ASC (μg/dL.90min)	
	Ghrelina	**GHRP-6**
1	1043	233
2	394	43
3	662	-215
4	737	176
5	47	201
6	193	379
7	849	387
8	419	29
9	374	496
Média	524	192
DP	322	218
EP	107	73

Tabela 18 – Resposta do ACTH expressa em Δ ASC após administração de ghrelina e GHRP-6 em controles.

Indiv.	Δ ASC (pg/mL.90min)	
	Ghrelina	GHRP-6
1	2202	1400
2	1084	-167
3	1217	-174
4	2273	270
5	41	274
6	507	819
7	801	649
8	2183	-61
9	3182	1842
Média	1499	539
DP	1015	711
EP	338	237

Tabela 19 – Resposta do cortisol expressa em Δ ASC após administração de ghrelina e GHRP-6 em pacientes com hipertireoidismo.

Indiv.	Δ ASC (μg/dL.90min)	
	Ghrelina	**GHRP-6**
1	866	-274
2	1145	691
3	1073	169
4	201	130
5	686	56
6	614	-256
7	462	305
8	901	658
9	-250	14
10	443	242
11	642	262
12	383	337
13	266	389
14	165	-117
15	152	-59
16	626	-142
17	394	117
18	-108	152
19	563	-356
20	463	-10
Média	484	115
DP	360	283
EP	80	63

Tabela 20 – Resposta do ACTH expressa em Δ ASC após administração de ghrelina e GHRP-6 em pacientes com hipertireoidismo.

Indiv.	Δ ASC (pg/mL.90min)	
	Ghrelina	GHRP-6
1	3367	-206
2	7007	4589
3	11148	1050
4	1780	741
5	1442	-78
6	838	-189
7	4511	521
8	3935	1706
9	2742	1085
10	24528	4901
11	2691	396
12	4666	1869
13	510	478
14	1017	-141
15	3879	-154
16	2065	299
17	1606	1541
18	1610	745
19	2325	-647
20	2112	23
Média	4189	927
DP	5377	1476
EP	1202	330

Livros Grátis

(http://www.livrosgratis.com.br)

Milhares de Livros para Download:

Baixar livros de Administração
Baixar livros de Agronomia
Baixar livros de Arquitetura
Baixar livros de Artes
Baixar livros de Astronomia
Baixar livros de Biologia Geral
Baixar livros de Ciência da Computação
Baixar livros de Ciência da Informação
Baixar livros de Ciência Política
Baixar livros de Ciências da Saúde
Baixar livros de Comunicação
Baixar livros do Conselho Nacional de Educação - CNE
Baixar livros de Defesa civil
Baixar livros de Direito
Baixar livros de Direitos humanos
Baixar livros de Economia
Baixar livros de Economia Doméstica
Baixar livros de Educação
Baixar livros de Educação - Trânsito
Baixar livros de Educação Física
Baixar livros de Engenharia Aeroespacial
Baixar livros de Farmácia
Baixar livros de Filosofia
Baixar livros de Física
Baixar livros de Geociências
Baixar livros de Geografia
Baixar livros de História
Baixar livros de Línguas